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ABSTRACT 
Background: Hypoplastic left heart syndrome (HLHS) is a congenital heart disease 
phenotype where the left side of the heart is severely underdeveloped and cannot support 
systemic circulation. Children with HLHS undergo the Fontan operation, where the caval 
veins are attached to the pulmonary artery, and the right ventricle pumps blood through the 
aorta. Children with HLHS with Fontan circulation (HLHS-FC) have a reduced exercise 
tolerance and suffer from autonomic dysfunction. Understanding the role of autonomic 
dysfunction by studying the exercise pressor reflex through the stimulation of mechano- and 
metaboreceptors could provide further insight on potential mechanisms contributing to 
exercise intolerance. We hypothesized than children with HLHS-FC would have an 
augmented exercise pressor response resulting in increased sympathetic stimulation through 
mechno- and metaboreflex (handgrip) and metaboreflex only (post-exercise circulatory 
occlusion, PECO) as defined by change in mean arterial pressure (MAP) versus healthy 
controls (CTL). Methods and Results: Nine HLHS-FC (f=3, m=6; 13±4 y) and 9 CTL (f=3, 
m=6; 13±3 y) rested supine for 10 minutes to assess heart rate variability (HRV) and resting 
physiologic parameters, then performed 2 minutes of 40% maximal voluntary contraction 
isometric handgrip exercise, followed by 3 minutes of PECO on the exercised arm. 
Continuous blood pressure, heart rate (HR), ventilation, and forearm blood flow (FBF) of the 
contralateral limb were measured throughout the protocol. Children with HLHS-FC had 
lower resting heart rate variability (HRV) values of standard deviation of normal R-R 
intervals (31.9±32.4 vs. 70.4±24.0; P = 0.011), root mean square of successive R-R interval 
differences (31.9±32.3 vs. 70.3±24.0; P = 0.011), percentage of consecutive normal R-R 
intervals that differ by more than 50ms (19.8±28.2 vs. 44.7±18.8; P = 0.043), low frequency 
power percentage (21.8±5.4 vs. 35.7±10.4; P = 0.003), high frequency power percentage 
(31.5±15.4 vs. 46.8±9.7; P < 0.023) than CTL. Mean arterial pressure (MAP) increased 
significantly less during handgrip (5±5mmHg vs 16±10mmHg; P < 0.001) and PECO 
(4±5mmHg vs 14±9mmHg P = 0.002) in HLHS-FC than CTL. There was a blunted exercise 
HR response in HLHS-FC compared to CTL (6±7 bpm vs. 24±8 bpm; P <0.001). Ventilation 
was lower in HLHS-FC than CTL during handgrip (0.32±1.15 L/min vs 3.36±3.94 L/min; P 
= 0.003). In HLHS-FC FBF increased substantially during PECO when compared to rest (0 
mL/min/m2 vs 19.8±32.6 mL/min/m2; P = 0.012) and handgrip (2.9±16.7 mL/min/m2 vs 
19.8±32.6 mL/min/m2; P = 0.036). Conclusion: Children with HLHS-FC suffer from 
 iii 
autonomic dysfunction, with a sympathovagal balance favouring the sympathetic nervous 
system, and contrary to our hypothesis, have a blunted exercise pressor reflex response to 
increased sympathetic stimulation. The exercise pressor reflex may play a key role in the 
exercise intolerance encountered by children with HLHS-FC.   
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CHAPTER ONE 
1.1 Introduction 
Congenital heart disease (CHD) is classified as lesions present at birth that affect the 
structure and function of the heart (9), and is the world’s leading birth defect (2, 10, 41). 
There is a wide range of severity in CHD, based on the size, location and other associated 
defects that come with each type of CHD. Approximately 1 in every 100 children in North 
America are born with CHD (2, 9, 10, 41).  In 2010 it was estimated that there were 
approximately 2.4 million people living with CHD in the United States (2, 10, 41) and 
257,000 in Canada (2, 9, 41). Approximately 85-90% of patients born with CHD in the past 
20 years are expected to survive until the age of 18 (2, 9), but fewer than 50% of individuals 
born with severe CHD survive to this same age (2). Consequently, this improvement in 
survival rate has contributed to a continually growing population of young adults who will 
require life-long cardiac care related to their CHD (9). Some CHD phenotypes have been 
linked to genetic disorders, maternal conditions and environmental factors; however risk 
factors for the majority of CHD phenotypes are unknown (2). Most individuals with CHD 
require surgical intervention to survive with 55% of all CHD surgeries performed in 
newborns or infants, and 38% of corrective surgeries on children between one and 18 years 
of age (2). Unfortunately, 50% of individuals with CHD require two or more surgeries, and 
surgical intervention may not necessarily be curative (2). Individuals with CHD typically 
have comorbidities related to their cardiac condition that include, in part, exercise intolerance 
and/or restrictions, irregular heart rhythms, valve dysfunction and pulmonary hypertension 
(2). These health problems increase the risk of heart failure, stroke, thrombosis, myocardial 
infarction, and premature/sudden death (2, 10). The cost burden related to CHD on the health 
care system in the United States in 2009 for individuals with CHD under the age of 18 was 
approximately $1.5 billion, and $280 million for adults (2) and $121.1 million in Canada for 
CHD related hospitalizations in 2013 (26). 
There are much fewer resources allocated for the care of adults with CHD when 
compared to patients with other cardiac problems such as myocardial infarctions or heart 
failure (10). This results in longer wait times for clinical visits, and surgical interventions for 
individuals with CHD (10). Of all the adults with CHD in Canada, 77% are considered “lost 
in the system”, suggesting that only 23% are actually followed by a physician on a semi-
annual basis (10). Of all cardiologists in Canada, only 1.8% have received formal training in 
managing patients with CHD (10). An emerging issue related to CHD treatment is the 
	 2 
unanticipated need for transferring health records of CHD patients from pediatric to adult 
care providers, which further contributes to inadequate patient care for many individuals with 
CHD (10). The health care disparities for those with CHD characterize an extremely 
underfunded and under-researched area when compared to other areas of cardiac disease care 
and research. 
1.2 Hypoplastic Left Heart Syndrome and Surgical Correction  
Hypoplastic left heart syndrome (HLHS) is a CHD phenotype where the left side of the 
heart is severely underdeveloped and cannot support systemic circulation (5). Systemic 
perfusion is decreased and without surgery, results in hypoxemia, acidosis and shock (4). The 
cause of the HLHS malformation is not fully understood (4). There are three surgeries a child 
must undergo in order to have a functional univentricular heart (4, 5). The first stage of 
palliation is known as the Norwood operation, which is performed at birth (4, 5). This 
surgery consists of creating a new aortic root and arch, disconnecting the pulmonary trunk 
from the pulmonary circulation and incorporating it into the systemic outflow tract (4, 5). A 
modified (Blalock-Taussig) shunt of approximately 3-4 mm in diameter is constructed in 
order to deliver blood to the lungs (4, 5). The shunting is performed in order to facilitate right 
ventricle ejection directly to the systemic circulation (4, 5). After this surgery the right 
ventricle is volume overloaded (approximately 250-350% of normal for body surface area) 
(18). This leads to overgrowth and eccentric hypertrophy of the ventricle, which can lead to 
dilation and pump dysfunction (18). At approximately 6-8 months of age the infant will 
undergo the second stage of palliation, the bi-directional Glenn operation (4, 5, 18). This 
procedure consists of anastomosis of the superior caval vein to the right pulmonary artery, 
and removal of the systemic-to-pulmonary arterial shunt (4, 5, 18). After this second phase of 
palliation the volume load of the ventricle is decreased to approximately 90% of normal for 
body surface area (18). Lastly, the Fontan operation is performed anywhere between 18 
months and 4 years of age (4, 5). This final stage of palliation involves routing the inferior 
caval venous blood through a conduit placed in the wall of the right atrium, into the 
pulmonary arteries, or through an extracardiac conduit (4, 5). This completes the total 
cavopulmonary connection (4, 5). The Fontan procedure further decreases volume load of the 
ventricle to approximately 50-80% of normal for body surface area (18). Therefore, through 
the process of palliation the right ventricle goes from overloaded and overstretched, to 
overgrown and deprived, which results in systolic and diastolic dysfunction (18). Despite 
advances in medical technology and operation methods, individuals with HLHS with Fontan 
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circulation (HLHS-FC) continue to have the highest mortality of all CHD phenotypes (4, 5) 
due to some of the physiological downfalls that the Fontan circulation creates. One 
underlying factor that may influence mortality is a disruption in the normal functioning of the 
autonomic system, which can adversely affect cardiovascular regulation at rest and during 
exercise (13, 24, 33). 
1.3 Fontan Circulation in HLHS  
 Patients with the Fontan circulation can develop a variety of problems that include, in 
part, decreased exercise capacity, ventricular systolic and diastolic dysfunction, 
dysrhythmias, and cyanosis, all of which contribute to early mortality (18). There are 5 CHD 
phenotypes that can be palliated using the Fontan circulation, including HLHS. Individuals 
with Fontan circulation often suffer from venous congestion, low cardiac output, a large thick 
hypocontractile ventricle, and autonomic dysfunction (18).  
 In the Fontan circulation, unlike a biventricular heart, there is no pump to propel 
blood flow into the pulmonary arteries (Figure 1.1). The systemic veins are directly 
connected to the pulmonary arteries, and thus deoxygenated blood is passively transported to 
the lungs. The capillary beds pool blood into neighboring capillary beds, which significantly 
decreases output, due to the non-pulsatile flow. The pulmonary resistance created in this 
circulation decreases venous return through the pulmonary vascular bed (17, 18), potentially 
thickening the alveolar capillary membrane (27). A thicker alveolar capillary membrane leads 
to decreased diffusing capacity leading to decreased blood oxygenation (27).  The increased 
pulmonary resistance also results in further congestion upstream and limits blood flow 
downstream, creating a “bottleneck-type” phenomenon (17, 18), which severely limits the 
performance of the whole circulatory system. The majority of the physiological and clinical 
conditions in those with Fontan circulation are due to the increased venous congestion and 
decreased cardiac output, caused by the increased pulmonary resistance (18). 
 In the Fontan circulation, the resistance within the capillary beds is the main 
contributing factor to low cardiac output (18). The blood flow through this system is 
determined by resistance within the capillary beds and the pressure on either side of the 
capillary bed. The pressure prior to the capillary bed is the systemic and pulmonary veins, 
and the pressure after the capillary bed is the ventricular filling pressure. However, the body 
can only tolerate a small range in ventricular filling pressure as well as in the systemic veins 
up to 20 mmHg (18). The inability to tolerate and change these pressures then leaves the 
main the determinant of cardiac output as the passive pooling created by the Fontan 
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circulation (18). The ventricle can provide enough driving force for the systemic circulation 
but is unable to compensate for the restriction that the Fontan circulation creates (18). The 
ventricle is incapable of pulling blood into the heart, as the amount of suction necessary is not 
physiologically possible (17, 18). The right ventricle is therefore no longer in control of 
cardiac output and cannot relieve any of the congestion in the systemic veins. Chronically the 
ventricle will dilate as a consequence of decreased flow, and the increased end-diastolic 
pressure, thus contributing to the worsening systemic venous congestion, and further 
decreasing output (17, 18). The Fontan circulation results in chronic blood volume 
deprivation of less than 70% of the preload expected for the size of the ventricle and leads to 
the development of the phenomenon termed ‘disuse hypofunction’ (18). Disuse hypofunction 
occurs from chronically low preload, which induces cardiac remodeling and dilation, and 
reduces ventricular compliance that subsequently increases filling pressure, all of which 
further reduces cardiac output (18). Although the ventricular diastolic suction is not the 
primary factor that reduces blood flow through the capillaries, over time ventricular function 
declines and thus goes from having a minimal role to becoming a major contributor of the 
declining Fontan circulation (15, 18).  
The Fontan circulation also creates an abnormal environment for the pulmonary 
vascular bed. There is decreased blood flow, desaturation, increased collateral flow, mixing 
of superior and inferior caval flows, no pulsatile flow, endothelial dysfunction, and an 
absence of periods of high flow and high pressure with vessel recruitment which would 
normally occur during times of physical exertion (18). The chronic low flow conditions 
created by the Fontan circulation results in global vasoconstriction in order to maintain 
perfusion, through the stimulation of the sympathetic nervous system (SNS), which increases 
pulmonary vascular pressure immensely (18, 30).  Therefore, the passive pooling of blood 
from capillary beds and the high pulmonary vascular resistance severely limits cardiac 
output, which in turn limits exercise capacity in individuals with the Fontan circulation.  
1.4 Exercise Intolerance in CHD Patients with Fontan Circulation  
Exercise intolerance is the single best independent predictor of mortality (21, 29), 
thus improving exercise tolerance of individuals with CHD should be a priority for improving 
quality of life and mitigating further disease risk. Successfully improving both quality of life 
and exercise capacity of individuals with CHD will help relieve some of the economic burden 
this population creates on the health care system as they age. The CHD phenotypes with one 
of the lowest levels of peak oxygen consumption and significant chronotropic incompetence 
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are those who have had the Fontan operation (14, 20, 23), such as those born with HLHS. 
Zajac and colleagues (45) determined that children with the Fontan circulation had 
significantly reduced peak VO2, anaerobic threshold, peak minute ventilation (VE) and peak 
heart rate (HR) compared to healthy controls, as well as an increased physiological dead 
space to tidal volume ratio at peak exercise. Diller and colleagues (14) found that adults with 
Fontan circulation had a peak oxygen consumption of 20.9 mL/kg/min, and an extremely 
blunted exercise HR of 140 bpm at peak exercise. Larsson et al. (25) had findings similar to 
Zajac (45) in that lung volumes, maximal expiratory flows, diffusion capacity, and maximal 
oxygen uptake were significantly lower than predicted values in adults, mean of 25 years, 
with the Fontan circulation. Kempny and colleagues (23) also reported similar results where 
adults with Fontan circulation, with an mean of 20 years of age, had a peak VO2 of 59% of 
predicted values (mean peak VO2 of 22.8 mL/kg/min). These data illustrate that individuals 
who have undergone the Fontan operation have one of the lowest exercise capacities among 
all CHD phenotypes. Giardini and colleagues (20) and Ohuchi (35) are the only to have 
characterized individuals with HLHS-FC from those with hypoplastic right heart syndrome to 
date. Both reports concluded that individuals with HLHS-FC had significantly lower peak 
VO2 compared to those with hypoplastic right heart syndrome (56% vs 64% of predicted 
peak VO2, respectively) and that the decline in peak VO2 was greater at rate of approximately 
3.7% of predicted values per year in HLHS-FC compared to 1.7% for those with hypoplastic 
right heart syndrome (20). These prior data suggest that individuals with the Fontan 
circulation have poor exercise tolerance and consequently are at increased risk for poor health 
outcomes (15, 29, 31, 32, 40)  
1.4.1 Pulmonary Vascular Resistance  
The physiological limitations created by the Fontan circuit become quite evident 
during exercise. For example, healthy adults are able to increase pulmonary blood flow 
greatly during peak exercise, where as individuals with Fontan circulation demonstrate a 
marginal increase if at all (17–19). Normally a reduction in pulmonary vascular resistance is 
accomplished though vasodilation and increased right ventricular work (18). The increased 
work of the right ventricle (subpulmonary ventricle) accelerates blood flow into the 
pulmonary vessels as well as aids in the increase of systolic pressures (18). Without a 
subpulmonary ventricle in the Fontan circulation, it is not possible to increase and accelerate 
blood flow to the pulmonary vessels (14, 18). Blood flow is further limited by the Fontan 
circulation because it has limited or even absent vascular reactivity and recruitment of vessels 
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(14, 18). Normally the number and cross-sectional area of capillaries are increased upwards 
of 100% during exercise with pulsatile flow (22). The recruitment and dilation of capillaries 
leads to a 30% reduction in pulmonary vascular resistance, this however is not present in 
Fontan circulation (22). Consequently, there is lower blood flow through the pulmonary bed 
than normal, due to increased pulmonary vascular resistance. Pulmonary vascular resistance 
increases due to a lack of recruitment and dilation of capillaries, which confers a lesser 
preload and therefore less output through an impaired Frank-Starling mechanism. 
1.4.2 Preload and Afterload 
 Preload of the heart has a large effect on cardiac output, which greatly determines 
exercise capacity. The lack of the subpulmonary pump, and the bottleneck-like physiology 
created by the passive capillary pooling, largely decreases the preload reserve (22, 30, 31). 
Stroke volume can therefore not increase without an increase in end-diastolic volume, and an 
increase in HR will only increase cardiac output a modest amount (30). Without a 
subpulmonary ventricle, the right ventricle is not able to generate adequate suction to pull 
blood through the capillaries in order to increase preload, which largely limits exercise 
capacity. Afterload is the force against which the heart must contract against in order to eject 
blood, and is determined by arterial blood pressure and vascular tone.  Afterload is higher 
both a rest and exercise in the Fontan circulation compared to healthy controls. This is due to 
the need to maintain perfusion pressure, which is decreased due to the decrease in cardiac 
output. The perfusion pressure is maintained through the increase of sympathetic nerve 
activity (SNA) (30).  The greater afterload is thus a consequence of reduced cardiac output, 
rather than the cause (22, 30). Although the ventricular afterload is not considered a limiting 
factor for exercise capacity, it may result in the heart having to generate greater work against 
the higher-pressure system. Because of the increase in filling pressures, poor ventricular 
filling and chronic exposure to high pressures can stimulate cardiac remodeling, subsequently 
leading to dilation and reduced compliance of the ventricle (17, 18) and the progression of 
heart failure. 
1.4.3 Heart Rate and Oxygen Uptake 
Heart rate and VO2 during peak exercise has been found to be significantly lower in 
individuals with the Fontan circulation than healthy controls (40). This is because VO2 is 
dependent on increasing cardiac output during exercise, and it is well known that cardiac 
output is decreased in these individuals (30). However, at any given cardiac output, 
individuals with the Fontan circulation will have a significantly higher relative VO2 than 
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healthy controls, which indicates some compensatory augmented use of O2 in working 
muscle (30). The decreased preload created by the Fontan circulation, due to the lack of a 
subpulmonary ventricle, decreases stroke volume and peak cardiac output (30, 31). The 
blunted exercise stroke volume is normally compensated for, in part, by the quick increase in 
HR; however, in HLHS-FC the HR response is blunted and does not adequately compensate 
for the needed increase in cardiac output for the exercise demand (30, 31). An increased HR 
at peak exercise may not improve exercise capacity in individuals with the Fontan, including 
those with HLHS-FC, as is seen in individuals with a biventricular heart (30). Impaired 
ventricular diastolic function, along with the decreased preload, likely impairs diastolic filling 
of the ventricle at increased HR (30). At increased HR there is a reduction in diastolic filling 
time that could potentially decrease stroke volume in a heart with diastolic dysfunction, 
which could contribute to a reduced exercise capacity. Therefore a further increase in HR 
would not promote an increase in stroke volume or ejection fraction, and thus would not 
increase exercise capacity (30).  
1.4.4 Role of Perfusion Pressure During Exercise 
The low cardiac output is problematic during exercise as the body requires adequate 
pressure for perfusion (to ensure enough blood travels to the lungs and becomes oxygenated) 
as well as to provide blood and oxygen to the exercising muscles in order to meet metabolic 
demands. In healthy individuals, the level of blood pressure is maintained through the arterial 
baroreflex mechanism. The baroreceptors are located in the aortic arch and carotid bodies, 
and detect changes in blood pressure through mechanical distortion. During exercise the 
baroreflex mechanism resets to function at a higher pressure level (30, 36). At moderate and 
high intensities of exercise the muscle mechano- and metaboreflex function to vasoconstrict 
vessels in order to maintain perfusion pressure (discussed in section 1.6) (6). However, in the 
Fontan circulation the muscle metaboreflex is involved in achieving the proper perfusion 
pressure both at rest and mild exercise intensities (30). This is due to the severely impaired 
cardiac autonomic nervous activity, especially the diminished vagal activity (30). Greater 
reliance on the metaboreflex at rest and mild exercise intensities may cause global 
vasoconstriction, which further limits blood flow to metabolically active tissues during 
exercise. An additional mechanism in the Fontan circulation that maintains or increases 
perfusion pressure is the respiratory pump, which may also serve to augment cardiac venous 
return during mild exercise (30).  
1.4.5 Ventilation 
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 Individuals with the Fontan circulation have a greater minute VE at any given 
submaximal exercise intensity than healthy controls (7, 30, 45). Minute VE will typically 
increase rapidly during exercise in individuals with the Fontan circulation and this could be 
attributed to an increase in dead space VE due to a mismatch between alveolar VE and 
perfusion that is potentially secondary to the lack of a subpulmonary ventricle (30). The 
perfusion is the blood flow from the heart to the lungs and into the capillaries where oxygen 
and nutrient exchange occur, whereas the alveolar VE is the process of drawing air into the 
lungs. The low cardiac output in this circulation results in lower production of carbon dioxide 
and lower VO2 during exercise (30). The imbalance between alveolar VE and perfusion 
occurs because the pooling from capillary bed to capillary bed is too slow, and thus when the 
air reaches the alveoli it can not undergo oxygen extraction due to the lack of blood flow in 
the capillary beds from breath to breath. The imbalance between VE and perfusion leads to a 
lower partial arterial pressure of carbon dioxide, and the body attempts to compensate for this 
is through excessive VE (30). This mismatch influences exercise capacity because the 
exercising muscles are unable to get adequate levels of oxygen to keep up with demands for 
exercise, and can result in hypoxia, faintness, shortness of breath, muscular fatigue or 
confusion, which can be common in individuals with the Fontan circulation. This lack of 
oxygen can also increase reliance on the lactic anaerobic system, resulting in the 
accumulation of lactic acid, which further limits exercise capacity. 
1.5 Autonomic Dysfunction in CHD 
Autonomic dysfunction is a common feature of CHD (13, 24, 33, 34, 36), and may 
contribute to exercise intolerance secondary to the underlying cardiac defect. Autonomic 
dysfunction occurs when there is an imbalance between the SNS and the parasympathetic 
nervous system (PNS). The sympathovagal balance is sympathetic dominant because of a 
reduction in vagus nerve tone (of the PNS), and results in three HR characteristics: a higher 
resting HR, blunted increase in HR during exercise, and slower HR recovery to baseline 
following exercise (14, 34). The blunted exercise HR is characteristic of chronotropic 
incompetence (14). These three HR features are common in patients with cardiovascular 
disease and CHD and are all associated with a decrease in exercise tolerance (15, 23), 
increased mortality (14, 23) and impaired autonomic function (34). Chronic high levels of 
sympathetic activity (SNA) results in global vasoconstriction at rest and during exercise, 
which increases total vascular peripheral resistance and thus blood pressure. This in turn, 
results in the heart having to contract against a higher afterload in order to eject blood from 
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the ventricle. If SNA remains chronically elevated the heart will undergo remodelling (42). 
The ventricle becomes enlarged due to increased filling pressures, and high afterload. 
Unfortunately, the heart will eventually become dilated, and reach a size where it is no longer 
efficient at pumping and the amount of blood left in the chamber after contraction (end 
systolic volume) begins to increase. This will further passively stretch the ventricle and 
further decrease heart pump function. This sustained sympathetic hyperactivity and increased 
blood pressure will then eventually lead to heart failure, to which there is no cure and the 
only option is a heart transplant (37, 42). 
 Heart rate variability (HRV) is a noninvasive technique for assessing autonomic 
control of the heart. HRV provides both time domain measures, and frequency domain 
measures. The three commonly interpreted frequency domain measures are low frequency 
(LF) (0.04-0.15 Hz) and high frequency (HF) (0.15-0.4 Hz) ranges, and a balance ratio 
between the two (LF/HF). The LF may represent sympathetic activity while the HF 
represents parasympathetic activity. Healthy individuals will have a lower LF/HF ratio, while 
those with autonomic dysfunction such as CHD and heart failure tend to have a higher LF/HF 
ratio, suggesting a more sympathetically dominant sympathovagal balance.  
 Both adults and children with the Fontan circulation have reduced resting HRV (8, 12, 
13, 38). Lower HRV frequency and time domains are not only associated with a sympathetic 
dominant nervous system but are associated with an increased mortality, and hospitalization 
risk (43, 44). Dahlqvist et al. (12) found that children with the Fontan circulation with 
univentricular hearts had a significantly reduced LF and HF domains at rest than healthy 
controls. Studies conducted by both Butera et al. (8) and Rydberg et al. (38) measured HRV 
using 24-hour Holter monitoring and were consistent with those of Dahlqvist. However, the 
sub-group analysis of Rydberg et al. (38) on children below the age of 10 and above the age 
of 10 revealed that HRV progressively decreased over time, as there were greater differences 
compared to controls in the older age group, than controls in the younger age groups. Davos 
and colleagues (13) measured HRV in 8 male adults with the Fontan circulation and also 
found that LF and HF signals were significantly reduced when compared to healthy controls, 
implying a sympathovagal balance favouring the SNS. Although studies are lacking, there is 
some evidence of autonomic dysfunction in individuals with the Fontan circulation in that 
they are sympathetic dominant, and that there is a potential aging effect. These prior reports 
are limited for the following reasons: First they do not separate HLHS-FC from other CHD 
that are palliated with the Fontan circulation. Therefore they lack homogeneity in their 
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Fontan group, even though these various Fontan phenotypes may be physiologically different 
from one another. Secondly there is a need for studies with larger samples sizes, and be 
prospective in nature to provide more in depth knowledge about the autonomic dysfunction in 
various types of CHD that have the Fontan circulation to further understand its effect on 
exercise capacity and help guide future therapies. 
1.6 The Exercise Pressor Reflex and its Possible Role for Exercise Intolerance in HLHS 
The exercise pressor reflex, which is made up of the mechano- and metaboreflex, can 
function as a mechanism for autonomic dysfunction, and demonstrate how it is exaggerated 
in individuals with CHD. The muscle mechano- and metaboreflex are muscle-based signaling 
mechanisms that stimulate the SNS, which results in increased HR, myocardial contractility, 
blood pressure and vasoconstriction (6, 16, 36). The vasoconstriction of vessels helps redirect 
blood flow to areas of the body that need it the most (36), such as the exercising muscles. 
Nitric oxide is released as a response to the shear stress of blood against the blood vessel wall 
at the muscle from the increased blood flow (36). Thus, nitric oxide induces vasodilation in 
muscle beds (16, 36), further redirecting blood flow to metabolically active tissues. This can 
be tested using handgrip exercise, which stimulates both the mechano- and metaboreflex, 
followed by post exercise circulatory occlusion (PECO) to isolate the stimulated 
metaboreflex only. In individuals who suffer from autonomic dysfunction, such as those with 
heart failure, the muscle metaboreflex is exaggerated (11, 28), and because of similarities in 
autonomic dysfunction between heart failure and HLHS-FC, may also be the case for 
children with HLHS-FC.  
During exercise, the exercise pressor reflex is activated by the muscle mechanoreflex 
and muscle metaboreflex thus increasing sympathetic activity. The mechanoreflex is 
comprised of type III afferent neurons that are stimulated by the physical distortion of the 
mechanoreceptors during muscle contraction. The metaboreflex is activated as follows: First, 
metabolites that are produced as a by-product during muscle contraction stimulate the 
metabolically sensitive type III and IV muscle afferent fibres in skeletal muscle (1, 16). The 
stimulation signals the SNS to increase activity resulting in vasoconstriction of the vessels 
that feed oxygen and blood to the exercising muscles (16). Endothelial dysfunction in 
sympathetically dominant individuals causes the vessels feeding O2 and blood to the 
exercising muscles to constrict rather than dilate during exercise. This is because the vessels 
are unable to override the sympathetic stimulation through the release of nitric oxide from the 
shear stress stimulation of the blood against the vessel walls. Normally the shear stress causes 
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nitric oxide to be released locally, inducing vasodilation, but sympathetic hyperactivity is so 
strong in those with autonomic dysfunction that it overrides the vasodilatory effects of the 
nitric oxide (39). The exaggeration of this sympathetic response has obvious implications on 
exercise tolerance (16), because vasoconstriction results in decreased blood flow to 
metabolically active tissues. With less blood available to the exercising muscles, there is less 
oxygen available, which results in higher muscle and blood lactate accumulation (3). Lactate 
accumulates due to a greater reliance on carbohydrate metabolism and/or reduced lactate 
removal (3). The muscle cells become too acidic as lactate levels increase and the body can 
no longer work at that intensity, thus limiting exercise capacity.  
The mechanisms that govern the decreased exercise tolerance in individuals with the 
Fontan circulation are not well understood. Further investigation of the autonomic 
dysfunction and potential influence that the muscle metaboreflex has on exercise tolerance in 
HLHS-FC is important. The muscle metaboreflex influences vasoconstriction and 
vasodilation, which thus influences mean arterial pressure response during exercise. This is 
important to further examine given that an exaggerated muscle metaboreflex response can 
exasperate blood pressure and exercise tolerance, which increase risk for adverse cardiac 
events. Homogeneity of individuals in the Fontan group is also important in further research 
as previous findings have found differences in exercise tolerance and maintenance of exercise 
ability, thus individuals with different pre-Fontan lesions may be physiologically different. 
Therefore, therapies for individuals with the Fontan circulation may have to be specific to the 
type of congenital pre-Fontan lesion.  
1.7 Purpose, Outcomes, and Hypotheses  
 The majority of clinical physiology research completed in children with CHD has 
been retrospective in nature, with small sample sizes, and lacks homogeneity of participants, 
specifically those with the Fontan circulation. Individuals with the Fontan circulation can 
include those with tricuspid atresia, pulmonary atresia with hypoplastic right heart syndrome, 
double inlet left ventricle, double outlet right ventricle, and HLHS. It is unknown if the 
physiology between various pre-Fontan CHD lesions that are palliated using the Fontan 
operation differ. 
1.7.1 Purpose 
 The purpose of this study was to determine the cardiovascular response to SNS 
activation subsequent to activation of the exercise pressor reflex from activation of the 
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mechano- and metaboreceptors (handgrip exercise) and metaboreceptors only (PECO) in 
children with HLHS-FC compared to healthy controls (CTL). 
1.7.2 Primary Hypothesis 
 We hypothesized that children with HLHS-FC will have an augmented mean arterial 
blood pressure (MAP) response during handgrip exercise, which will remain elevated above 
rest during isolation of the muscle metaboreflex during PECO.  
1.7.3 Secondary Hypotheses 
 We hypothesized that children with HLHS-FC will have a blunted HR during 
handgrip exercise, and return towards baseline levels during PECO. We hypothesized that 
forearm blood flow (FBF) would be reduced, and systemic vascular resistance (SVR) would 
be greater in HLHS-FC, compared to CTL during handgrip and PECO. We hypothesized that 
VE, and respiratory rate (f) would be greater, and tidal volume (TV) would lower in HLHS-
FC than CTL during handgrip and PECO. 
1.7.4 Primary Outcome 
 The primary outcome was the change in MAP from rest to handgrip and PECO. 
1.7.5 Secondary Outcomes 
 Secondary outcomes were the change in HR, FBF, SVR, VE, TV, and f from rest to 
handgrip and PECO. 
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Figure 1.1 Fontan circulation. The superior and inferior vena cava become connected to the 
pulmonary arteries. Blood by-passes the heart, through the pulmonary artery, to the lungs, 
and out through the pulmonary vein. The blood goes through the pulmonary vein goes into 
the left and right atrium, to the right ventricle and finally out through the aorta. Retrieved 
from: Children’s Hospital of Philadelphia http://www.hearts-of-hope.org/congenital-heart-
disease/hlhs-treatment/stage-3-fontan/ 	
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CHAPTER TWO 
2.1 Introduction  
 Children with Fontan circulation have a reduced exercise tolerance, this may be 
secondary to autonomic dysfunction (15, 21, 24, 26, 30). There are a number of pre-Fontan 
congenital heart disease phenotypes that are palliated using the Fontan operation, such as 
hypoplastic left heart syndrome (HLHS). Children with HLHS lack a functional left ventricle 
and are characterized as one of the congenital heart disease phenotypes with the lowest 
exercise tolerance (8, 9, 11, 14, 16, 20, 30). Given that exercise intolerance is the single best 
predictor of mortality (13, 18), improving exercise tolerance and quality of life in this 
population should be a priority. However, the mechanisms underlying the severe exercise 
intolerance in HLHS with Fontan circulation (HLHS-FC) are not well understood. 
Our understanding of determinants of exercise intolerance in Fontan patients is 
limited by prior studies not accounting for the various Fontan phenotypes. Notably, children 
with HLHS-FC have lower peak VO2 (56% predicted) than children with a hypoplastic right 
ventricle (64% predicted), and peak VO2 tends to decline at a faster rate in HLHS-FC (3.7%/ 
year) compared to hypoplastic right heart syndrome patients (1.7%/year) (11). This prior 
work strongly suggests that the unfavorable physiologic changes that determine peak VO2 in 
HLSH-FC are more significant than other pre-Fontan etiologies.  
One mechanism that may have an important role in the exercise intolerance observed 
in HLHS-FC could be related to the exercise pressor reflex. The exercise pressor reflex is 
modulated by mechano- and metaboreflexes that are activated during exercise to increase 
sympathetic activity. The mechanoreflex is stimulated by distortion of the mechanoreceptors 
during muscle contraction and the metaboreflex is stimulated by metabolic by-products 
produced during muscle contraction. The subsequent increase in sympathetic activity 
contributes to vasoconstriction and an exaggerated blood pressure response in individuals 
with autonomic dysfunction, which is characteristic of heart failure (1, 27, 29) and CHD 
patients (6, 15, 23). An exaggerated blood pressure response can adversely affect exercise 
tolerance due to vasoconstriction and reduced blood flow to exercising muscles. The exercise 
pressor reflex has not been studied in children with HLHS-FC, and therefore its contributing 
role to exercise intolerance observed in these children remains unknown.  
 The purpose of this study was to determine the cardiovascular response to 
sympathetic stimulation during exercise that engages mechano- and metaboreceptors 
(handgrip exercise) and metaboreceptors only (post-exercise circulatory occlusion, PECO) in 
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children with HLHS-FC versus healthy controls (CTL). The primary hypothesis was that 
mean arterial pressure (MAP) would be augmented and blood flow reduced as a consequence 
of an exaggerated exercise pressor reflex in children with HLHS-FC versus CTL. 
2.2 Methods 
2.2.1 Participants 
 A total of 18 participants were recruited for this study; 9 with HLHS-FC and 9 
healthy controls (CTL) matched for sex and age. Inclusion criteria for HLHS-FC was to have 
undergone the Fontan procedure, be between the ages of 8-18 at the time of testing, be able to 
perform handgrip exercise for two minutes and follow verbal commands related to the 
experimental procedures. Participants with HLHS-FC were recruited through the Pediatric 
Cardiology Department at the Royal University Hospital in Saskatoon, Saskatchewan. A 
pediatric cardiologist screened patients and identified 10 individuals who met our inclusion 
criteria. These families were contacted and 9 agreed to participate. Individuals in the CTL 
group were recruited through word of mouth and social media. Inclusion criteria for the CTL 
group included being free from cardiovascular and respiratory disease, ability to perform 2 
minutes of isometric handgrip exercise, and able to follow verbal commands related to the 
experimental procedures. Parents and/or legal guardians of child participants provided written 
consent (Appendix A and B) and children participants provided written assent (Appendix C 
and D). This study was approved by the University of Saskatchewan Research Ethics Board 
(Appendix E). 
2.2.2 Testing Protocol 
Participants laid supine on a bed throughout the entirety of the test in a temperature 
controlled dimly light room. Participants were then instrumented with a finger blood pressure 
cuff and 3 lead ECG. Following a 10-minute resting period, a 5-minute HRV recording 
session was performed. Following, maximal handgrip strength was determined by having 
participants squeeze a handgrip dynamometer (MLT004/ST, ADInstruments, Bella Vista, 
NSW, Australia) with maximal effort three times with a 1-minute rest period between trials. 
Using the average of the three maximal trials, 40% maximum handgrip voluntary contraction 
(MVC) was calculated and used for subsequent testing. Participants then had a brief 
familiarization period where they practiced a continuous handgrip exercise test using a visual 
target of 40% MVC. Participants were then instrumented with a facemask that was connected 
to a pneumotach for the purpose of collecting ventilation data. On the left arm we determined 
probe placement for the duplex vascular ultrasound in order to measure FBF from the 
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brachial artery throughout the protocol. The probe was fastened into place using a custom 
probe holder. Once instrumented, the experimental protocol began with recording the 
participant at rest for 3 minutes, followed by 2 minutes of 40% MVC, and 3 minutes of post 
exercise circulatory occlusion (PECO). Five seconds before the 40% MVC stage was 
completed, a blood pressure cuff was inflated on the exercising arm at 50 mmHg above 
resting systolic blood pressure (circulatory occlusion) for 3 minutes. Protocol representative 
data highlighting handgrip exercise, PECO and blood pressure is shown in Figure 2.1. 
2.2.3 Heart Rate Variability (HRV) and Heart Rate (HR) 
Datum were recorded and integrated using a Powerlab data acquisition system and 
analysed using LabChart 8 software (Powerlab 16/30; ADInstruments). Continuous HR was 
measured using a 3-lead ECG in a lead II configuration. HRV analysis was performed on a 5-
minute ECG recording sampled at 1000 Hz, and time domain and frequency domain data was 
calculated. Time domain HRV parameters included the standard deviation of normal R-R 
intervals (SDRR), the root mean square of successive R-R interval differences (RMSRR), 
and the percentage of consecutive normal R-R intervals that differ by more than 50ms 
(pNN50%). Power spectral HRV analyses included low frequency (LF) power (0.04 – 0.15 
Hz), high frequency (HF) power (0.15 – 0.45 Hz), and the LF/HF ratio.  
2.2.4 Mean Arterial Pressure (MAP) 
 Continuous mean arterial pressure was recorded using finger photoplethysmography 
(Finopress Midi, Amsterdam, The Netherlands) on the left hand. Resting blood pressure was 
measured using an automated blood pressure cuff (WelchAllyn, Skaneateles Fall, United 
States) for the purpose of calibrating our blood pressure readings using LabChart 8 (Units 
Conversion function) at time of automated measurement.  
2.2.5 Forearm Blood Flow (FBF) 
 Continuous blood flow was measured from the left brachial artery (non-excising limb) 
using duplex ultrasound (Logiq e, Wauwatosa) with a 12L-RS linear probe (5.0-13.0 MHz). 
Diameter and pulsed wave blood velocity data was measured from 10 consecutive beats on 
the ultrasound machine. Blood flow was calculated as π × (D/2)2 × Vmean × 60, where 
Vmean was mean blood velocity (cm/s) and D was arterial diameter (cm). Blood flow was 
then scaled to body surface area (BSA; Mosteller’s method (17)) to account for differences in 
body size within and between HLHS-FC and CTL groups.  
2.2.6 Systemic Vascular Resistance (SVR) 
 Systemic vascular resistance was calculated as the ratio between MAP and FBF.  
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2.2.7 Ventilation 
 Continuous flow was recorded breath-by-breath with a heated pneumotach (3830 
series; Hans Rudolph, Shawnee) and flow was calibrated using a known volume to obtain 
VE, TV and f.  
2.2.8 Data Analysis 
 Resting, handgrip and PECO data for HR, VE, TV, f, and MAP were analyzed as 
average values over 30 seconds. Resting, handgrip and PECO data for FBF and SVR were 
analyzed as average values over 10 beats within each 30-s window. To account for individual 
differences in physiologic responses that inherently contribute to increased group variance 
that subsequently masks physiological differences between groups, values during handgrip 
and PECO were subtracted from the respective baseline value for each participant (7, 10, 12). 
Baseline values were subsequently modified to a reference value of zero and were included in 
the analysis in order to facilitate addressing the study hypothesis. Data was analyzed with a 2 
× 3 repeated measures ANOVA (group: HLHS-FC, CTL × condition: rest, handgrip, PECO) 
in SPSS (v24.0, Chicago, IL, USA) and Tukey post-hoc tests (SigmaPlot v13.0, Systat 
Software Inc. San Jose, CA, USA). If the assumption of sphericity was violated, degrees of 
freedom were adjusted using the Greenhouse-Geisser correction. If the assumption of 
homogeneity of variance was violated, between group analyses were performed with the 
Mann-Whitney U Rank Sum test. Data are reported as mean ± SD change from resting values 
(Δ). Demographic data, HRV data, and baseline physiologic characteristics were analyzed 
using unpaired t-tests. Significance for all testing was determined when P < 0.05. Appendix F 
details degrees of freedom, Greenhouse-Geisser corrected degrees of freedom, F-values, and 
specific non-parametric testing when used. 
2.3 Results 
2.3.1 Demographics 
 Age and BMI were not different between HLHS-FC and CTL groups (Table 2.1). 
Although there was no statistical difference the children with HLHS-FC tended to be smaller 
in stature, weight, and BMI. All CTL reported being regularly physically active (defined as 
60+ min × ≥ 3 days/week), where as all HLHS-FC reported being physically inactive. All 
children with HLHS-FC all took a daily dose of aspirin.  We were satisfied with MVC effort 
levels during this protocol and individual participant MVC values are reported in Appendix 
G.  
2.3.2 Heart Rate Variability 
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 Children with HLHS-FC had lower SDRR, RMSSD (31.9±32.3 vs. 70.3±24.0; P = 
0.011), pRR50% (19.8±28.2 vs. 44.7±18.8; P = 0.043), LF% (21.8±5.4 vs. 35.7±10.4; P = 
0.003) and HF% (31.5±15.4 vs. 46.8±9.7; P < 0.023) than the CTL (Table 2.2). There was no 
difference in LF/HF ratio between groups (0.83±0.40 vs. 0.82±0.39; P > 0.05). 
2.3.3 Baseline Physiologic Characteristics 
 Resting MAP, HR, FBF and VE did not differ between groups at rest (Table 2.3). 
Participants in the HLHS-FC group had a lower TV (0.59±0.23 vs. 0.92±0.18; P = 0.005), 
and higher f (22±4 vs 17±4; P = 0.01) and SVR (2.61±1.6 vs. 1.13±0.56; P = 0.018) than the 
CTL group. 
2.3.4 Mean Arterial Pressure 
 Children with HLHS-FC had a lower change in MAP from rest to handgrip (5±5 
mmHg vs. 16±10 mmHg; P < 0.001) and rest to PECO (4±5 mmHg vs. 14±9 mmHg; P = 
0.002) than CTL (Figure 2.2). The increase in MAP was significant in CTL from rest to 
handgrip (16±10 mmHg; P < 0.001) and from rest to PECO (14±9 mmHg; P < 0.001), but 
not in HLHS-FC. 
2.3.5 Heart Rate 
 Children with HLHS-FC had a lower change in HR from rest to handgrip (6±7 bpm 
vs. 24±8 bpm; P < 0.001) compared to CTL (Figure 2.3). The increase in HR was significant 
from rest to handgrip (24±8 bpm; P < 0.001) and decreased significantly from handgrip to 
PECO (24±8 bpm vs 4±7; P < 0.001) in CTL. 
2.3.6 Forearm Blood Flow  
 There was no difference in FBF between groups (Figure 2.4).  
2.3.7 Systemic Vascular Resistance  
 Children with HLHS-FC had a significantly lower SVR during PECO than during 
handgrip (0.29±0.67 mmHg/ml/min vs -0.38±0.65 mmHg/ml/min; P = 0.001) There was no 
difference in SVR between groups (Figure 2.5). 
2.3.8 Respiratory Measures 
 VE was lower during handgrip in HLHS-FC than CTL (0.32±1.15 L/min vs 
3.36±3.94 L/min; P = 0.047) (Figure 2.6). In CTL, VE increased during handgrip from rest 
(3.36±3.94 L/min; P < 0.001) decreased significantly from handgrip to PECO (3.36±3.94 vs 
1.24±2.59; P = 0.025). The change in TV was lower in HLHS-FC during handgrip than CTL 
(-0.01±0.04 ml vs 0.17±0.18 ml; P = 0.024) (Figure 2.7). In CTL, TV increased from rest to 
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handgrip (0 0.17±0.18 ml; P = 0.002) and decreased from handgrip to PECO (0.17±0.18 ml 
vs 0±0.10; P = 0.003), but not in HLHS-FC. There was no difference in f between groups 
(Figure 2.8). 
2.4 Discussion 
The major novel finding of this study is that, contrary to our hypothesis, MAP was 
lower during handgrip and PECO in HLHS-FC compared with CTL. During exercise, MAP 
normally increases and following circulatory occlusion MAP is expected to remain elevated 
due to sympathetic stimulation through isolation of the muscle metaboreflex (observed in 
CTL; Figure 2.2). HLHS-FC participants compared to CTL had a severely blunted MAP 
response to handgrip where we observed a negligible increase in MAP. When followed by 
circulatory occlusion, MAP remained elevated as expected but the magnitude of this response 
was also blunted. Our observation of an overall lower MAP during both mechano- and 
metaboreflexes suggests that the exercise pressor reflex is blunted in children with HLHS-
FC. To our knowledge, this is the first study to characterize the exercise pressor reflex in 
children who have undergone the Fontan operation due exclusively to HLHS-FC.  
2.4.1 Mechanisms Underlying a Blunted Exercise Pressor Reflex in HLHS-FC 
 Our data show that there was no difference in MAP at baseline between HLHS-FC 
and CTL. However, participants in the HLHS-FC group had a markedly reduced MAP 
response to both handgrip exercise and isolated muscle metaboreflex sympathetic stimulation 
than CTL. Prior research characterizing the blood pressure response to exercise in patients 
with the Fontan circulation is lacking. There has only been one study to date that employed 
handgrip exercise and circulatory occlusion to determine the muscle metaboreflex in both 
children and adults with Fontan circulation (4). A limitation of this previous work was the 
inclusion of a small sample (n = 6), none of whom had an univentricular right heart (4). 
Brassard et al. (4) reported that only diastolic blood pressure differed between Fontan 
patients and CTL, where Fontan patients had a significantly higher diastolic blood pressure 
response to circulatory occlusion. Ohuchi (21, 22) found resting and peak exercise systolic 
blood pressures to be lower in patients with Fontan circulation than CTL. The lower blood 
pressure response to exercise is problematic as MAP has a role in maintaining proper 
perfusion pressure. In healthy individuals, parasympathetic withdrawal at exercise onset is 
responsible, in part, for increasing cardiac output to achieve proper perfusion and MAP. As 
exercise continues, mechano- and metaboreflexes from the contracting muscles and 
vasoconstrictive mechanisms provide additional sympathetic stimulation to further increase 
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MAP to necessary levels to maintain proper perfusion (20). The metaboreflex, when 
stimulated, is responsible, in part, for increasing or maintaining blood pressure to redistribute 
blood flow and blood volume through the vasoconstriction of non-active tissues. The increase 
in blood flow and blood volume through active muscle beds will decrease vascular resistance 
substantially. Elevated levels of blood pressure and metabolic by-product accumulation 
further trigger sympathetic activation. In the current investigation, our data suggests there is 
an impaired MAP response to exercise in children with HLHS-FC and therefore implicates 
abnormal function in one of these regulating systems. Patients with Fontan circulation tend to 
display less vagal tone at rest as suggested by our observation of a reduction in time domain 
HRV and alterations in the HRV frequency domain, which is consistent with several prior 
reports (5, 6, 24, 25). Results from our study support previous findings of significantly 
reduced HRV, however the previous studies looked at multiple Fontan phenotypes, making 
the participant group heterogeneous. Our study is the first to assess HRV in a very 
homogeneous group of children with HLHS-FC. This study further supplements the evidence 
of autonomic dysfunction in these individuals, which is of importance as it influences heart 
rate kinetics which is an independent predictor of cardiac events in adults with cardiovascular 
disease and various types of CHD (25). Cumulatively, hemodynamic abnormalities and 
autonomic dysfunction may adversely influence the ability of HLHS-FC participants to 
regulate MAP during exercise. 
2.4.2 Heart Rate 
 Baseline measures of HR were similar between groups. Conflicting reports exist 
about whether resting HR is higher (4, 21, 22), similar (20, 25), or lower (15) in individuals 
with the Fontan circulation than CTL. It is important to note that the previous studies were 
conducted on heterogeneous groups of children with the Fontan circulation, and did not 
separate the different Fontan phenotypes.  
During handgrip, the increase in HR was significantly lower in HLHS-FC than CTL. 
Changes in HR were significantly higher in CTL during handgrip when compared to rest and 
PECO. This observation supports prior and well documented findings of a blunted exercise 
HR in Fontan patients (4, 20–22, 25, 28). Two studies conducted by Ohuchi et al. (20, 25) 
reported an exaggerate rate of increase in HR at exercise onset, but an overall blunted HR 
response to exercise. The author suggested the rapid increase in HR occurred in an attempt to 
compensate for a lack of increase in stroke volume, and the blunted response could 
potentially be due to intrinsic sinus node dysfunction following cardiac surgery, as it is 
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associated with exercise-related HR dynamics (20, 25). Ohuchi et al. (22, 25) also reported 
measures of high sympathetic nerve activity (characteristic of patients with the Fontan 
circulation), and this may contribute to the blunted HR increase with exercise and is what 
contributes the most to low peak exercise HR. This is important to note as the change in HR 
from baseline to exercise is a predictor of future cardiac events, as the exercise HR reflects 
global cardiac autonomic dysfunction, and is an independent predictor in adult patients with 
ischemic heart disease and various CHD (25). Our findings of a blunted HR during handgrip 
and PECO provide further insight into exercise intolerance mechanisms.  
2.4.3 Forearm Blood Flow Responses to Handgrip and PECO 
 We hypothesized the HLHS-FC group to have an exaggerated increase in SVR and 
decrease in FBF. We observed that FBF was similar between groups at rest and did not differ 
during handgrip and PECO between groups. However, we observed a trend in HLHS-FC 
with a FBF increase during PECO compared to rest and handgrip. One possible explanation 
for our observation of increased FBF during PECO could be secondary to the blunted 
exercise pressor reflex as evidenced the low MAP and HR responses during handgrip and 
PECO (for MAP only). Because HLHS-FC demonstrated a blunted HR during handgrip, it 
may follow that contractility, although not measured, may have compensated to facilitate 
cardiac output during handgrip. Subsequently, during PECO, ventricular contractility may 
have remained elevated thereby working to maintain an elevated cardiac output. An increased 
cardiac output coupled with hyporesponsive blood vessels to sympathetic activity, as 
evidenced by the low MAP response during PECO, may have facilitated a reduction in 
resistance during PECO and could lead to an increase in FBF. It is important to note that our 
observation is limited by not having simultaneously assessed cardiac output during the 
protocol, and FBF did not have a significant interaction. 
 Participants with HLHS-FC had significantly higher SVR at baseline than CTL, but 
the change in SVR during handgrip and PECO did not differ between groups. However, the 
change in SVR was significantly higher during handgrip than PECO in HLHS-FC, which 
could result in a decreased trend observed in FBF. Although further investigation is needed, 
we believe that because the exercise pressor response is blunted, there is a hypotensive 
response to sympathetic activity, which results in some vasodilation and thus a reduced SVR 
and increased FBF. 
2.4.4 Respiratory Responses to Handgrip and PECO 
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 There was no difference at baseline for VE between groups, but contrary to previous 
findings (19, 20), CTL had significantly higher increase in VE during handgrip than HLHS-
FC. Studies conducted by Ohuchi et al. (19, 20) demonstrated that VE at any given intensity 
was higher in Fontan patients than CTL. They attributed enhanced VE to be secondary to one 
of two things; increased dead space due to a mismatch between ventilation and perfusion or 
reduced lung compliance from pulmonary congestion as is seen in heart failure patients (19, 
20). Shafer et al. (28) did not find differences in VE between Fontan patients and healthy 
controls during cycle ergometer graded exercise tests. In that study, patients could potentially 
already be working near maximum contractility when cycling and therefore an increase in 
intrathoracic pressure during inspiration would not further increase cardiac output (28). Key 
differences between prior work and the present investigation include our experiment 
employing supine small muscle isometric handgrip exercise compared to cycle ergometry or 
treadmill testing that employs a large muscle mass (3, 19, 30).  
The change in VE was significantly higher in CTL during handgrip compared to rest 
and PECO, which is consistent with previous reports in healthy individuals (2). It is 
anticipated that VE will increase during exercise, as the body needs to compensate for an 
increase in oxygen demand from the working muscles; this however did not occur in HLHS-
FC.   
Our data show that children with HLHS-FC had significantly lower baseline TV, and 
lower change in TV during handgrip than CTL, which is similar to previous studies (20). This 
finding suggests that there may be a potential increase in dead space created from the 
ventilation – perfusion mismatching that occurs during exercise in HLHS-FC (20). 
 As expected, the CTL change in TV was significantly higher during handgrip when 
compared to rest and PECO. During exercise, when there is an increased demand for O2, VE 
and TV increase to accommodate this demand. During exercise carbon dioxide production is 
increased, and an increase in TV allows for the removal of that carbon dioxide through 
exhalation. 
Baseline data for f was significantly higher in HLHS-FC than CTL. When considering 
our VE and TV findings, it is not surprising that f at rest was higher in HLHS-FC. Since VE 
was similar at rest and TV was reduced, f would have to be increased in order to compensate 
for a lower TV, in order to maintain a similar VE to CTL. Our findings support previous 
studies in that there was no difference between or within groups during the experimental 
protocol (20). 
	 27 
2.5 Conclusion 
 The present study demonstrated for the first time in a homogeneous group of children 
with HLHS-FC and the Fontan circulation that these children have a blunted exercise pressor 
reflex as defined by a reduced change in MAP and HR during handgrip exercise and reduced 
MAP during PECO compared to CTL. The blunted exercise pressor reflex in HLHS-FC was 
accompanied by an abnormal decrease in SVR from handgrip to PECO and a blunted 
ventilation response to HG and PECO. Cumulatively, our findings provide a possible 
mechanistic basis for the observed exercise intolerance in children with HLHS-FC.  
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Table 2.1: Participant demographics 
  CTL  HLHS-FC 
Age, yrs          13 ± 3        13 ± 4 
Sex (f:m)   3:6  3:6 
Height (cm)       161 ± 17       148 ± 17 
Weight (kg)    55 ± 22    40 ± 18 
BMI (kg/m2)  20 ± 5  18 ± 5 
BSA (m2)    1.5 ± 0.4    1.2 ± 0.4 
 
Values are mean ± SD. BSA, body surface area. CTL, controls; HLHS-FC, hypoplastic left 
heart syndrome with Fontan circulation 
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Table 2.2: Heart rate variability 
  CTL  HLHS-FC  P-value 
SDRR  75 ± 24  32 ± 32  0.011 
RMSSD  70 ± 24  32 ± 32  0.011 
pNN50%  45 ± 19  20 ± 28  0.043 
LF%  36 ± 10         22 ± 5               0.003 
HF%  47 ± 10   32 ± 16  0.023 
LF/HF  0.82 ± 0.39   0.83 ± 0.40  0.941 
 
Values are mean ± SD. SDRR, standard deviation of normal R-R intervals; RMSSD, root 
mean square of successive R-R interval differences; pNN50%, percentage of consecutive 
normal R-R intervals that differ by more than 50 ms; LF, low frequency power; HF, high 
frequency power; LF/HF, low frequency to high frequency ratio; CTL, controls; HLHS-FC, 
hypoplastic left heart syndrome with Fontan circulation.  
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Table 2.3: Baseline physiologic characteristics 
  CTL  HLHS-FC  P-value 
MAP (mmHg)  75 ± 10  78 ± 10  0.401 
HR (beats/min)        69 ± 9        75 ± 6  0.096 
FBF (ml/min/m2 )  41.3 ± 38.0  62.1 ± 46.0  0.312 
SVR(mmHg/ml/min)  1.13 ± 0.56     2.61 ± 1.6  0.018 
VE (L/min)     14.9 ± 3     12.4 ± 3.8  0.141 
TV (L)  0.92 ± 0.18  0.59 ± 0.23  0.005 
f (breaths/min)        17 ± 4        22 ± 4  0.010 
 
Values are mean ± SD. MAP, mean arterial pressure; HR, heart rate; FBF, forearm blood 
flow; SVR, systemic vascular resistance; VE, ventilation; TV, tidal volume; f, respiratory 
rate; CTL, controls; HLHS-FC, hypoplastic left heart syndrome with Fontan circulation. 
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Figure 2.1: Representative data. Representative data from a participant in hypoplastic left 
heart syndrome with Fontan circulation (HLHS-FC) group. Blood pressure was measured 
throughout the protocol (bottom panel), with mean arterial pressure (MAP) in white. First 
three minutes was resting data, followed by two minutes of handgrip isometric exercise at 
40% maximum voluntary contraction (MVC) as seen in the top panel. Fifteen seconds before 
handgrip exercise was complete a blood pressure cuff was inflated to 50 mmHg above resting 
systolic values for three minutes (middle panel).  
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Figure 2.2: Change in mean arterial pressure (MAP). Change in MAP in hypoplastic left 
heart syndrome with Fontan circulation (HLHS-FC) group and control (CTL) group from rest 
during handgrip and post-exercise circulatory occlusion (PECO). *Significantly different 
between groups (P<0.01); ƚSignificantly different from rest within group (P<0.001). Values 
are means ± SD.	
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Figure 2.3: Change in heart rate (HR). Change in HR in hypoplastic left heart syndrome with 
Fontan circulation group (HLHS-FC) and control group (CTL) from rest during handgrip and 
post-exercise circulatory occlusion (PECO). *Significantly different between groups 
(P=0.001); ‡Significantly different from handgrip within CTL group (P<0.001).	
ƚSignificantly different from rest within CTL group (P<0.001). Values are means ± SD.	
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Figure 2.4: Change in forearm blood flow (FBF). Change in FBF in hypoplastic left heart 
syndrome with Fontan circulation (HLHS-FC) group and control (CTL) group from rest 
during handgrip and post-exercise circulatory occlusion (PECO). Values are means ± SD.	
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Figure 2.5: Change in systemic vascular resistance (SVR). Change in SVR in hypoplastic left 
heart syndrome with Fontan circulation (HLHS-FC) group and control (CTL) group from rest 
during handgrip and post-exercise circulatory occlusion (PECO). ‡Significantly different 
from handgrip within HLHS-FC group (P=0.001). Values are means ± SD.	
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Figure 2.6: Change in ventilation (VE). Change in ventilation in hypoplastic left heart 
syndrome with Fontan circulation (HLHS-FC) group and control (CTL) group from rest 
during handgrip and post-exercise circulatory occlusion (PECO). *Significantly different 
between groups (P=0.047). ‡Significantly different from handgrip within group (P=0.025).	
ƚSignificantly different from rest within group (P<0.001). Values are means ± SD.	
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Figure 2.7: Change in tidal volume (TV). Change in tidal volume in hypoplastic left heart 
syndrome with Fontan circulation (HLHS-FC) group and control (CTL) group from rest 
during handgrip and post-exercise circulatory occlusion (PECO). *Significantly different 
between groups (P=0.024). ‡Significantly different from handgrip within group (P=0.003).	
ƚSignificantly different from rest within group (P<0.001). Values are means ± SD.	
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Figure 2.8: Change in respiratory rate (f). Change in f in hypoplastic left heart syndrome with 
Fontan circulation (HLHS-FC) group and control (CTL) group from rest during handgrip and 
post-exercise circulatory occlusion (PECO). Values are means ± SD. 
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CHAPTER THREE 
3.1 Discussion 
 The present study demonstrated for the first time, in a homogeneous sample of 
children with hypoplastic left heart syndrome (HLHS) and the Fontan circulation (HLHS-
FC), a blunted exercise pressor reflex as defined by a lower change in mean arterial pressure 
(MAP) and heart rate (HR) during handgrip exercise and lower MAP during post-exercise 
circulatory occlusion (PECO) compared to controls (CTL). The exercise pressor response 
may play a key role in the autonomic dysfunction encountered by children with HLHS-FC. 
Our findings further support that children with HLHS-FC have reduced resting heart rate 
variability (HRV) and thus have a relatively sympathetic predominant sympathovagal 
balance. However, contrary to our hypothesis, MAP was blunted during handgrip and PECO, 
rather than augmented. In addition, our finding of a blunted HR response during handgrip 
exercise compared to CTL is consistent with prior reports (2, 25, 26, 29, 35, 37). We also 
observed an abnormal trend in FBF and a concomitant decrease in SVR in during PECO in 
children with HLHS-FC compared to CTL. Children with HLHS-FC demonstrated a 
decreased ventilation (VE) and tidal volume (TV) response to exercise. Cumulatively, our 
study illustrates that the autonomic dysfunction in children with HLHS-FC may affect the 
exercise pressor reflex. Based on several key similarities between children with HLHS-FC 
and adults with heart failure (HF, detailed below), we hypothesized that our experimental 
protocol (handgrip exercise and PECO) would adversely exacerbated MAP. 
3.1.1 Cardiovascular Similarities between Heart Failure (HF) and Fontan Patients  
We hypothesized that children with HLHS would have an exaggerated metaboreflex 
response and thus an exaggerated increase in MAP as is seen in HF patients (6, 7, 19), based 
on similarities in pathophysiology between both patient groups such as reduced VO2, exercise 
HR, HRV, cardiac output, ejection fraction and high central venous pressure.  
First and foremost, both individuals with the Fontan circulation and HF patients have 
reduced exercise tolerance objectively measured by VO2. Kempny et al. (20) compared CHD 
phenotypes and found that individuals with the Fontan circulation had one of the lowest peak 
percent predicted VO2 values (59% predicted). Giardini et al. (16) compared predicted 
percent peak VO2 values and found children with HLHS ranged from 46-66% of predicted 
scores, which was lower than children with hypoplastic right heart syndrome who ranged 
from 53-75% of predicted scores.  Shafer et al. (35) found that healthy children had a 50% 
higher increase in VO2 during submaximal exercise than children with the Fontan circulation. 
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Results from three studies originating from the same lab (26, 27, 29) consistently found that 
children with the Fontan circulation had significantly reduced peak VO2 ranging from 18-28 
ml/kg/min. Patients with HF have significantly reduced exercise capacity with VO2 peak of 
50% of healthy control values (21–23, 31, 36).  
 Children with the Fontan circulation and HF patients both have a blunted HR 
response to exercise. Shafter et al (35) found that exercise HR in children with the Fontan 
circulation was reduced by approximately 25%. Ohuchi found similar findings in four studies 
(26–29) where HR during exercise was significantly reduced in Fontan patients. Similarly, 
HF patients also suffer from chronotropic incompetence (3, 22).  
 Both patients with HF and HLHS-FC have a reduced resting HRV, suggesting marked 
changes in sympathovagal balance favoring relative sympathetic predominance at rest. 
Dahlqvist et al. (8) found that children with the Fontan circulation have significantly reduced 
LF and HF spectral signals at rest. Butera (4) and Rydberg (33) both determined HRV with 
24-hour Holter monitoring in Fontan children and observed the same reduction in HRV as 
Dalvqvist (8). Davos and colleagues (10) measured HRV in adults with the Fontan 
circulation and also described similar findings of decreased HRV. Reduced resting HRV is 
also a typical characteristic of HF patients. Ponikowski et al. (31) and Bilchick et al. (1) not 
only found that HRV spectral domains were reduced in HF patients, but that these reductions 
also independently predicted mortality and sudden death. Both HLHS-FC and HF patients 
have unfavorable changes in HRV and are at increased risk for adverse cardiac events and 
mortality.  
 Reduced cardiac output and low ejection fraction are also characteristic of both 
Fontan and HF patients. Ohuchi et al. (27–29) assessed cardiac output and ejection fraction in 
Fontan patients and observed both to be significantly reduced when compared to controls at 
rest, but cardiac output and ejection fraction were not determined during exercise. Shafer et 
al. (35) also found cardiac output to be reduced at rest and during submaximal cycle 
ergometry exercise in children with the Fontan circulation compared to healthy controls. It 
appears that on average Fontan patients have an ejection fraction ranging from 50-80% of 
normal values when indexed for body surface area (11, 15, 28). Cardiac output during 
exercise in healthy individuals increases substantially, whereas Fontan patients increase only 
about 50% of that of controls (13–15, 34). Patients with HF may achieve less than 50% of 
maximal cardiac output than that achieved by healthy controls during exercise (3, 30), and 
cardiac output is also decreased at rest. Ejection fractions in HF are also markedly reduced 
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compared to healthy controls during rest and exercise at approximately 25% of control values 
(5).  
  Lastly, both HF and HLHS-FC demonstrate characteristically high central venous 
pressures, which results in the heart having a higher ventricular filling pressure in an attempt 
to increase ventricular diastolic filling. In three studies conducted by Ohuchi and colleagues 
(26, 27, 29) the authors reported central venous pressure at rest to be significantly higher in 
Fontan patients (5-15 mmHg) than in healthy controls (2-8 mmHg); this is also true for heart 
failure patients (24). This is worrisome as high central venous pressures are associated with 
increased risk for mortality (9). 
3.1.2 Factors Influencing Mean Arterial Pressure  
Considering the above characteristic pathophysiological similarities between HF and 
HLHS-FC we hypothesized the exercise pressor reflex in children with HLHS-FC would be 
exaggerated during exercise, similar to patients with HF. This however was not the case and 
children with HLHS-FC demonstrated a blunted exercise pressor reflex as evidenced by a 
lower MAP during handgrip and PECO. 
 The arterial baroreflex is one mechanism that influences blood pressure regulation 
during exercise by controlling HR, contractility and SVR. An alteration in the baroreflex in 
HLHS-FC may help explain the blunted MAP response observed during handgrip exercise 
and PECO. Specifically, the baroreflex detects changes in blood pressure through 
baroreceptors, which are activated when stretched or deformed in the walls of the carotid 
sinuses and the aortic arch (32). When the baroreceptors are activated there is a decrease in 
sympathetic activity and increase in parasympathetic activity which in turn results in a 
decrease in cardiac contractility and SVR in order to decrease blood pressure (12, 32). During 
exercise, the baroreflex continues to regulate blood pressure by resetting around the exercise-
induced elevated blood pressure to work at a new, higher “baseline” blood pressure (called 
the “set point”). However, when baroreflex sensitivity is reduced, as has been reported in 
individuals with the Fontan circulation (27, 28), a greater change in blood pressure is 
required in order to elicit an concomitant increase in sympathetic activity and increase HR 
and SVR. The reported decreased baroreceptor sensitivity in HLHS may be secondary to 
stiffening of the aortic and carotid sinus walls, subsequently conferring a greater pressure 
requirement for baroreceptor distortion or from a lack of unloading of the cardiopulmonary 
baroreceptors (12).  
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The cardiopulmonary baroreceptors are also mechanically sensitive receptors but are 
located in the heart, lungs, and great veins. Unloading of the cardiopulmonary baroreceptors 
caused by a decrease in central venous pressure improves arterial baroreceptor sensitivity and 
aids in the resetting of that reflex (12). The augmented central venous pressure in individuals 
with the Fontan circulation may continually load the cardiopulmonary baroreceptors during 
exercise, thus preventing the arterial baroreflex from resetting in order to function at a higher 
blood pressure level. Previous work has shown that baroreflex sensitivity is reduced in 
individuals with the Fontan circulation (27, 28), however this was not a feasible outcome in 
our study. We did attempt to measure baroreflex sensitivity from resting HR and systolic 
blood pressure data using the sequence method. However, this method requires the detection 
of spontaneous changes in blood pressure in three or more cardiac cycles accompanied with a 
change in HR in the same direction (positive or negative). The slope of the regression line 
between systolic blood pressure and R-R interval changes is used as an index of arterial 
baroreflex sensitivity. After performing the baroreflex sensitivity analysis, we found adequate 
sequences on only three HLHS-FC and six CTL. We were therefore unable to properly 
analyze and interpret the role of baroreflex sensitivity on blood pressure regulation in the 
present study. 
 Another major determinant of MAP is cardiac output, which has been shown to be 
reduced in children with the Fontan circulation (13–15, 28, 35). However, the cause for the 
low cardiac output is due primarily to the lack of a subpulmonary ventricle in the Fontan 
circulation (13–15), whereas a diastolic dysfunction and cardiac remodeling are responsible 
for a reduction in cardiac output in HF (5, 18, 22). In individuals with the Fontan circulation 
there is a blunted increase in stroke volume during exercise because central venous pressure 
is substantially high (27). The high venous pressure results in less blood flow to the heart and 
therefore the volume of blood pumped per beat can only increase slightly with an increase in 
contractility (26), thus resulting in a reduced cardiac output and MAP. 
Heart rate is severely blunted during exercise in HLHS-FC, which reduces cardiac 
output and thus exercise tolerance. The blunted HR has been suggested to be a consequence 
of the autonomic dysfunction that characterizes this patient group (29). An interesting 
observation in our HLHS-FC study group was that although the participants demonstrated a 
blunted exercise pressor reflex, they were still able to complete the handgrip exercise task. 
Prior reports involving large muscle mass exercise in HLHS-FC have demonstrated a blunted 
low HR (26, 29, 35), and presumably blunted cardiac output. In the current study, however, 
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children with HLHS-FC were able to complete the handgrip exercise task, suggesting that 
perhaps there was a potential peripheral adaptation at the muscle that facilitated the exercise. 
An adaptation such as increased capillarization despite physical inactivity could causes 
children with HLHS-FC to be more efficient at extracting O2 at the muscle. Greater oxygen 
extraction may compensate for poor cardiac output and could be one possible adaptive 
mechanism related secondary to exercise intolerance. Indeed, patients with HF classically 
demonstrate an often higher arterial-venous O2 content difference at peak exercise compared 
to health controls (17). However, cardiac output was not directly measured in this study. 
3.2 Clinical Relevance  
 The findings from the current study have characterized novel mechanisms that, in 
part, may contribute to the previously reported exercise intolerance in children with HLHS-
FC. Investigation of the determinants of exercise intolerance in children with HLHS-FC will 
aid in providing more specific and appropriate evidence-based exercise and rehabilitation 
guidelines that are currently lacking for HLHS-FC. Once key exercise determinants are 
established for individuals with HLHS-FC, then prospective exercise intervention studies can 
be conducted to examine the efficacy of targeted exercise therapies ameliorating exercise 
intolerance, thereby improving quality of life and conferring reduced mortality risk in this 
poorly understood population.  
3.3 Limitations 
 There were a number of limitations with the present study. The size of our sample 
could be perceived as a limitation, however we believe ours to be the only experiment of this 
kind performed on only children with HLHS. Because of limitation of prior work not 
differentiating pre-Fontan lesion, having an extremely homogenous group was a priority (16). 
Another limitation of our study was that vascular diameters were determined manually from 
duplex vascular ultrasound, and thus are prone to bias and variability. It is difficult to directly 
compare our investigation to other previous studies as ours employed supine isometric 
handgrip (small muscle mass) exercise, whereas previous studies used graded exercise tests 
on a cycle ergometer or treadmill, and did not utilize a PECO protocol (25, 27, 29, 35). 
However, by using handgrip exercise we were able to have a controlled experimental design 
that enabled specific determination of the possible exercise pressor reflex role on exercise 
tolerance. 
3.4 Future Suggestions 
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 Future studies should compare children with HLHS-FC to CTL using a larger muscle 
mass to confirm if findings during exercise and PECO are similar to the smaller muscle mass 
experimental model used in the study. Assessing stroke volume, cardiac output and 
baroreflex sensitivity would provide a more complete picture as to the cardiovascular 
regulation in children with HLHS during exercise and PECO. Lastly, determining FBF in the 
exercising limb would provide a more physiologic representation of blood flow regulation 
where sympathetic vascular control is countered with local metabolic vasodilatory stimuli. 
3.5 Conclusion 
 The present study demonstrates for the first time in a homogenous group of children 
with HLHS and the Fontan circulation that the exercise pressor reflex is blunted, as 
evidenced by a reduced change in MAP and HR during handgrip and reduced MAP during 
PECO when compared to CTL. The blunted exercise pressor reflex was accompanied by a 
blunted VE response during handgrip and PECO. Cumulatively, our findings provide insight 
for a mechanistic basis for exercise intolerance observed in children with HLHS-FC and may 
help guide future studies, as well as exercise and therapy guidelines in this population. 
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A	Pilot	Health	Intervention	Study	of	Children	with	Congenital	Heart	Defects:	CHAMPS	–	Children’s	
Healthy	Heart	Camp	in	Saskatchewan	
	
	
PRINCIPAL	INVESTIGATOR:		 	 	 	
Dr.	Marta	Erlandson,	College	of	Kinesiology	 			 		
Email:	marta.erlandson@usask.ca	 	 	 	
Phone:	306-966-1071	
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Dr.	Corey	Tomczak,	College	of	Kinesiology	 	 Dr.	Kristi	Wright,	University	of	Regina		
Email:	corey.tomczak@usask.ca		 	 	 Email:	Kristi.wright@uregina.ca		
Phone:	306-966-1066	 	 	 	 	 Phone:	306-585-4772	
		
CO-INVESTIGATOR:	
Dr.	Ashok	Kakadekar,	Pediatric	Cardiology	
Email:	a.kakadekar@usask.ca			
	
Study	funded	by:	Children’s	Hospital	Foundation	of	Saskatchewan	
_______________________________________________________________________	
	
INTRODUCTION	
Your	child	is	invited	to	participate	in	this	study	because	he/she	is	between	the	ages	of	7-15	and	has	a	
clinical	diagnosis	of	a	congenital	heart	defect.		This	study	is	looking	at	the	physical	and	mental	health	
of	children	with	congenital	heart	defects	compared	to	children	without	congenital	heart	defects.		
The	study	is	also	examining	a	1-week	summer	camp	style	physical	activity,	heart	health	and	
psychological	health	intervention	for	children	with	congenital	heart	defects.		
	
Your	child’s	participation	is	voluntary.	It	is	up	to	him/her	and	you	to	decide	whether	or	not	he/she	
wishes	to	take	part.	If	your	child	wishes	to	participate,	you	will	be	asked	to	sign	this	form.	If	he/she	
does	decide	to	take	part	in	this	study,	he/she	is	still	free	to	withdraw	at	any	time	and	without	giving	
any	reasons	for	the	decision.	
	
If	your	child	does	not	wish	to	participate	in	the	study,	it	will	not	affect	his/her	medical	care	in	any	
way.	Pediatric	cardiologists	and	clinic	staff	will	not	know	whether	your	child	chooses	to	participate	
or	not.		
	
Please	take	time	to	read	the	following	information	carefully.	You	can	ask	the	researcher	to	explain	
any	words	or	information	that	you	do	not	clearly	understand.	You	may	ask	as	many	questions	as	you	
need.	Please	feel	free	to	discuss	this	with	your	family,	friends	or	family	physician	before	you	decide.	
	
WHO	IS	CONDUCTING	THE	STUDY?		
The	study	is	led	by	Dr.	Marta	Erlandson,	a	faculty	member	in	the	College	of	Kinesiology	at	the	
University	of	Saskatchewan.	This	research	is	funded	by	the	Children’s	Hospital	Foundation	of	
Saskatchewan.	Neither	the	University	nor	any	of	the	investigators	will	receive	any	direct	financial	
benefit	for	conducting	this	study.		
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WHY	IS	THIS	STUDY	BEING	DONE?	
Congenital	heart	defects	are	the	world’s	leading	type	of	birth	defect.	Children	with	congenital	heart	
defects	have	higher	rates	of	physical	inactivity	and	obesity	compared	to	healthy	peers.	This	may	
mean	that	children	with	congenital	heart	defects	are	more	likely	to	have	chronic	conditions	such	as	
heart	disease	and	poor	bone	health	(osteoporosis)	later	in	life.	It	has	also	been	found	that	children	
with	congenital	heart	defects	have	high	levels	of	anxiety	around	physical	activity	participation.	While	
we	know	that	children	with	congenital	heart	defects	have	higher	rates	of	obesity	little	is	known	
about	their	muscle,	bone	and	heart	health.	This	study	will	look	at	important	aspects	of	the	physical	
and	mental	health	of	children	with	congenital	heart	defects.			
	
Past	research	has	highlighted	the	need	for	programming	for	children	with	congenital	heart	defects	
that	involves	healthy	lifestyle	counseling	and	physical	activity	participation.	Parents	of	children	with	
congenital	heart	defects	have	reported	having	minimal	resources	for	knowing	how	to	establish	safe	
levels	of	physical	activity	for	their	children.	Currently,	there	is	no	such	program	in	Saskatchewan	or	
Canada	to	help	parents	and	children	with	congenital	heart	defects.	This	study	will	be	the	first	step	in	
developing	a	physical	activity,	heart	health	and	psychological	health	program	for	children	with	
congenital	heart	defects	and	their	families.			
	
WHO	CAN	PARTICIPATE	IN	THE	STUDY?		
Your	child	is	eligible	to	participate	in	this	study	if	he/she	is	aged	7-15	years	and	has	been	cleared	to	
participate	by	the	pediatric	cardiology	team	at	the	Royal	University	Hospital	(RUH).	Your	child	is	not	
eligible	if	he/she:	(1)	had	cardiac	surgery	in	the	last	six	months;	(2)	has	cyanotic	congenital	heart	
disease;	(3)	has	significant	valve	disease;	(4)	has	any	physical	condition	limiting	physical	activity;	
and/or	(5)	is	unable	to	complete	all	the	questionnaires.		
	
WHAT	DOES	THE	STUDY	INVOLVE?	
	
The	study	involves	two	or	three	parts.		
	
Part	1	involves	a	single	visit	to	the	Physical	Activity	Complex	(PAC)	at	the	University	of	Saskatchewan	
in	June,	July	or	August.	This	visit	will	take	approximately	four	hours.	During	this	visit,	your	child	will	
be	asked	to	complete	a	form	with	his/her	personal	information	(such	as	name,	telephone	number,	
and	date	of	birth)	and	will	also	be	asked	to	complete,	with	your	assistance	if	needed,	questionnaires	
about	his/her	general	health	history,	physical	activity	and	psychological	well-being	(health	related	
anxiety	questionnaires).	We	will	measure	the	following:	
• Your child’s height, sitting height, weight, waist circumference, and limb length. 
• Your child’s body composition using DXA (dual energy x-ray absorptiometry). DXA is a 
scan that is done while your child lies on his/her back on what looks like a padded x-ray table. 
We will measure his/her total body, hip and spine. The scan assesses total body bone, muscle 
and fat tissues. The scans take approximately 10 minutes and will expose your child to a 
minimal amount of radiation (less than 5µSV).  
• Your child’s bone shape and strength using a peripheral quantitative computed tomography 
(pQCT) scan of his/her non-dominant arm and lower leg (each scan takes about 2 minutes). 
For these scans your child will sit on a padded chair with his/her arm or leg resting on a 
support. All tests are painless and non-invasive. pQCT is a form of x-ray and therefore does 
emit a small amount of radiation. The total radiation for all measurements (DXA and pQCT) 
is less than 4µSV; this is comparable to the amount of background radiation a person receives 
in two days from naturally-occurring sources in Saskatchewan. For reference a cross-country 
flight could expose a person to about 30µSV of radiation (http://www.hc-sc.gc.ca/hc-ps/ed-
ud/respond/nuclea/measurements-mesures-eng.php).  All scans will be administered by 
trained and certified personnel.  
• Your  child’s heart health using the following seven tests:    
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1. Three small stickers connected with a wire to our computer will be attached to your child’s 
shoulders and stomach. The information from the stickers will tell us about the activity of 
your child’s heart. The stickers are gentle on the skin and are the same ones that the 
hospital uses when it measures your child’s heart activity. We will measure your child’s 
heart activity while he/she lies on his/her back for ten minutes. This test does not cause any 
discomfort and there are no health risks associated with it.  
2. The health of your child’s blood vessels will be measured using a special machine at the 
same time as the first test. The machine uses a special pen that is placed on the skin to give 
a picture of your child’s blood pressure. Your child will need to lie still for about 5 
minutes. This test does not cause any discomfort and there are no health risks associated 
with it.  
3. Your child’s nerves and blood vessels will tested by having your child squeeze a hand 
gripper for two minutes. After this we will inflate a blood pressure cuff and will keep it 
inflated for two to three minutes. While the cuff is inflated we will monitor your child’s 
blood pressure. The handgrip test will be repeated without inflating a blood pressure cuff. 
During both handgrip tests we will measure blood pressure. This test can cause a slight 
tingling sensation in the arm from the blood pressure cuff. The sensation goes away when 
the cuff pressure is released. 
4. Your child’s fitness will be tested with a low-intensity walk test to see how far he/she can 
walk in 6 minutes. Your child will walk at his/her own speed back and forth in a hallway 
for 6 minutes. We will measure your child’s heart rate and blood pressure before and after 
the walk test. The walk test is safe for those with heart problems because it is of low 
intensity and your child chooses how fast or slow he/she walks. We will closely monitor 
your child during the walk test. 
5. Your child’s fitness will also be testing using a stationary exercise bike while they breathe 
through a special mouthpiece that measures how much oxygen they use during exercise. 
This test will take 5 to 10 minutes. We will measure your child’s blood pressure and 
monitor their breathing and heart activity.  This test is also safe for those with heart 
problems in whom their condition is stable. As an extra precaution, a pediatric resident will 
monitor this test. This test will take a total of 30 minutes. 
6. Your child’s heart structure and function will be assessed using cardiac ultrasound. This 
assessment will entail your child lying restfully on their side for 30 minutes. During this 
time, Dr. Timothy Bradley (Pediatric Cardiologist) will use a special ultrasound machine to 
take pictures of your child’s heart. The assessment will entail performing a series of images 
by placing a probe in different positions over your child’s chest. This assessment is very 
safe, low risk, is entirely non-invasive, and places no stress on your child. This test will 
take a total of 30 minutes. 
7. Your child’s blood vessel function will also be measured using vascular ultrasound. This 
assessment will be performed while your child is doing the handgrip exercise test described 
in #3 above. The assessment will entail placing a probe over your child’s arm. This 
assessment is very safe, low risk, is entirely non-invasive, and places no stress on your 
child. This test will not add any time to your child’s session. 
 
	
After	the	visit	to	the	University,	your	child	will	be	asked	to	wear	an	accelerometer	for	7	consecutive	
days.	An	accelerometer	is	a	type	of	motion	sensor	that	measures	your	child’s	physical	activity.	It	is	a	
small	device	that	will	be	worn	around	your	child’s	waist	on	an	elastic	belt.	He/she	will	be	asked	to	
put	it	on	first	thing	in	the	morning	and	wear	it	all	day	except	when	bathing,	swimming	or	playing	
contact	sports.		During	your	visit	at	the	University,	you	will	be	provided	with	an	addressed	and	
stamped	envelope	to	return	the	accelerometer	after	the	seven	days	of	wear.		
				
Part	2	of	the	study	involves	a	week	long	summer	day-camp.	This	portion	of	the	study	will	take	place	
at	the	College	of	Kinesiology,	University	of	Saskatchewan	from	August	10-14th,	2015.	The	program	
will	run	from	9am-5pm	and	will	consist	of	three	parts:	(1)	physical	activity	promotion	and	
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participation;	(2)	heart	health	and	health	behavior;	and	(3)	psychological	well-being.	Your	child	will	
be	grouped	based	on	age:	younger	(7-12)	and	older	(13-15)	and	take	part	in	activities	that	are	age-
appropriate.	The	physical	activity	portion	will	be	of	low	to	moderate	intensity	and	comply	with	
established	international	recommendations	for	children	with	congenital	heart	defects.	Example	
activities	include:	swimming	and	ball	and	racquet	sports.	Your	child	will	wear	an	accelerometer	for	
the	week	long	camp	to	assess	the	amount	of	physical	activity.	Your	child	will	also	engage	in	sessions	
on	healthy	eating,	heart	health,	and	how	to	detect	his/her	physical	limitations	(heart	health	and	
health	behavior	part).	The	psychological	wellbeing	part	will	focus	on	teaching	your	child	healthy	
psychosocial	coping	mechanisms	with	a	special	emphasis	on	understanding	and	coping	with	anxiety	
related	to	physical	activity	participation.	The	program	will	incorporate	many	important	health	
aspects	but	will	do	so	in	a	fun,	summer	camp	style	of	programming.	During	the	Camp	we	will	also	
assess	your	child’s	physical	literacy;	their	ability	to	run,	jump,	throw	and	catch	and	have	you	fill	out	a	
questionnaire	about	your	perceptions	of	their	ability	to	move	confidently.	To	assess	your	and	your	
child’s	satisfaction	with	the	program	we	will	ask	both	of	you	to	fill	out	a	short	questionnaire	when	
you	pick	your	child	up	on	the	last	day.	After	the	week	long	program	your	child	will	be	mailed	an	
accelerometer	to	once	again	wear	for	seven	consecutive	days	along	with	an	addressed	and	stamped	
envelope	to	return	it	after	the	seven	days.		
	
Part	3	of	this	study	will	include	a	small	sample	of	parents	and	children	so	you	may	or	may	not	be	
invited	to	participate	in	a	focus	group	held	at	the	Social	Science	Research	Lab	at	the	University	of	
Saskatchewan	in	late	August	or	early	September.	The	focus	group	will	look	at	satisfaction	with	the	
camp,	what	participants	liked	and	would	like	to	see	changed	in	future	programming.		
	
If	you	consent,	we	may	take	photographs	of	your	child	during	the	study	that	would	be	used	only	for	
research	and/or	teaching	presentations.	These	photographs	would	be	de-identified	so	your	child’s	
face	would	not	be	recognizable.		
	
WHAT ARE THE BENEFITS OF PARTICIPATING IN THIS STUDY?  
There	may	be	no	direct	benefit	to	your	child	from	participating	in	this	study.	Your	child	will	get	to	
participate	in	the	week	long	program	aimed	to	teach	your	child	how	to	detect	his/her	physical	
limitations	with	regard	to	physical	activity	and	provide	him/her	with	the	tools	cope	with	health	
related	physical	activity	anxiety	and	hopefully	empower	him/her	to	be	more	physically	active.	It	is	
hoped	that	the	information	gained	from	this	study	can	be	used	in	the	future	to	create	a	sustainable	
program	for	children	with	congenital	heart	defects.		
	
ARE	THERE	POSSIBLE	RISKS	AND	DISCOMFORTS?	
The	risks	of	participating	are	minimal.	The	fitness	test	on	a	stationary	bike	will	assess	your	child’s	
exercise	capacity.	During	this	test,	your	child	may	feel	a	few	minutes	of	physical	fatigue	that	comes	
with	exercise.	They	also	may	experience	some	leg	soreness	as	a	consequence	of	this	test,	but	this	
should	disappear	within	2	days.	This	stationary	bike	test	is	safe	and	the	intensity	of	how	hard	your	
child	exercises	is	determined	by	your	child.	As	an	extra	precaution,	a	pediatric	resident	will	supervise	
the	stationary	bike	test.	As	stated	above,	the	bone	measures	(DXA	and	pQCT)	will	expose	your	child	
to	a	minimal	amount	of	radiation.	These	tests	are	very	low	risk;	the	total	radiation	dose	for	each	
study	visit	is	less	than	half	of	that	of	a	standard	chest	x-ray.	As	with	any	physical	activity	there	is	the	
potential	of	physical	injury	or	discomfort.	Your	child	may	experience	sore	muscles	after	the	six	
minute	walk	test.	If	your	child	experiences	soreness	it	will	not	last	very	long.	We	have	taken	every	
precaution	to	ensure	all	physical	activity	during	the	camp	will	be	safe	for	your	child	and	a	pediatric	
resident	will	be	at	the	weeklong	camp	in	the	unlikely	event	that	medical	attention	is	needed.				
				
WHAT HAPPENS IF I DECIDE TO WITHDRAW? 
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Your	child’s	participation	in	this	research	is	voluntary.	He/she	may	withdraw	from	this	study	at	any	
time.	You	do	not	have	to	provide	a	reason.	Your	child’s	relationship	with	the	department	of	pediatric	
cardiology	will	not	be	affected	and	pediatric	cardiologists	and	clinic	staff	will	not	be	informed.	
	
If	your	child	chooses	to	enter	the	study	and	then	decides	to	withdraw	later,	all	data	collected	about	
him/her	during	his/her	enrolment	will	be	retained	for	analysis.		
	
WHAT WILL THE STUDY COST ME? 
You will not be charged for any research-related procedures and your child will not be paid for 
participating in this study. Your parking costs at the University for the Part 1 visit will be covered.  
	
WHAT HAPPENS IF SOMETHING GOES WRONG?  
In the unlikely event that your child is injured while participating in this research, appropriate medical 
care will be provided at no cost to you. By signing this document, you and your child do not waive 
any of your legal rights.   
	
WILL	MY	TAKING	PART	IN	THIS	STUDY	BE	KEPT	CONFIDENTIAL?	
Your	child’s	confidentiality	will	be	respected.		No	information	that	discloses	your	child’s	identity	will	
be	released	or	published	without	your	specific	consent	to	the	disclosure.		The	information	collected	
in	this	study	will	be	stored	in	the	locked	office	of	the	PI,	Dr.	Marta	Erlandson.	The	results	of	this	
study	may	be	presented	in	a	scientific	meeting	or	published,	but	your	child’s	identity	will	not	be	
disclosed.	If	you	consent	we	may	use	de-identified	photographs	of	your	child	for	the	purpose	of	
research	and/or	teaching	presentations.			
	
	
WHO	DO	I	CONTACT	IF	I	HAVE	QUESTIONS	ABOUT	THE	STUDY?	
If	 you	 have	 any	 questions	 or	 desire	 further	 information	 about	 this	 study	 before	 or	 during	
participation,	 you	 can	 contact	 Marta	 Erlandson	 by	 phone	 at	 306-966-1071	 or	 by	 email	 at	
marta.erlandson@usask.ca.	
	
If	you	have	any	concerns	about	your	child’s	rights	as	a	research	participant	and/or	your	experiences	
while	participating	in	this	study,	contact	the	Chair	of	the	University	of	Saskatchewan	Research	Ethics	
Board,	at	306-966-2975(out	of	town	calls	1-888-966-2975).	The	Research	Ethics	Board	is	a	group	of	
individuals	(scientists,	physicians,	ethicists,	lawyers	and	members	of	the	community)	that	provide	an	
independent	review	of	human	research	studies.	This	study	has	been	reviewed	and	approved	on	
ethical	grounds	by	the	University	of	Saskatchewan	Research	Ethics	Board.		
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o I have read (or someone has read to me) the information in this consent form. 
o I understand the purpose and procedures and the possible risks and benefits of the study.  
o I was given sufficient time to think about it. 
o I had the opportunity to ask questions and have received satisfactory answers. 
o I	understand	that	my	child	is	free	to	withdraw	from	this	study	at	any	time	for	any	reason.		
o I	have	been	informed	that	there	is	no	guarantee	that	this	study	will	provide	any	benefits	to	
my	child.		
o I give permission to the use and disclosure of my child’s de-identified information collected 
for the research purposes described in this form. 
o I understand that by signing this document I do not waive any of my or my child’s legal 
rights. 
o I understand I will be given a signed copy of this consent form. 
	
I	 agree	 to	 allow	 de-identified	 photographs	 of	 my	 child	 to	 be	 used	 for	 research	 and/or	 teaching	
presentations:	
□	Yes	
□	No	
	
I	agree	to	allow	my	child	to	participate	in	this	study:	
	
	
Printed	name	of	person	providing	consent:	______________________________	
Signature	of	Consenting	Parent:		 	Date	_______________	
	
	
Printed	name	of	person	obtaining	consent:	________________________________	
Signature			 	Date	___________	
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   PARTICIPANT INFORMATION AND PARENTAL CONSENT FORM  
	
A	Pilot	Health	Intervention	Study	of	Children	with	Congenital	Heart	Defects:	CHAMPS	–	Children’s	
Healthy	Heart	Camp	in	Saskatchewan	
	
PRINCIPAL	INVESTIGATOR:		 	 	 	
Dr.	Marta	Erlandson,	College	of	Kinesiology	 			 		
Email:	marta.erlandson@usask.ca	 	 	 	
Phone:	306-966-1071	
	
CO-PRINCIPAL	INVESTIGATORS:		
Dr.	Corey	Tomczak,	College	of	Kinesiology	 	 Dr.	Kristi	Wright,	University	of	Regina		
Email:	corey.tomczak@usask.ca		 	 	 Email:	Kristi.wright@uregina.ca		
Phone:	306-966-1066	 	 	 	 	 306-585-4772	
		
CO-INVESTIGATOR:	
Dr.	Ashok	Kakadekar,	Pediatric	Cardiology	
Email:	a.kakadekar@usask.ca	
	
Study	funded	by:	Children’s	Hospital	Foundation	of	Saskatchewan	
_______________________________________________________________________	
	
INTRODUCTION	
Your	child	is	being	invited	to	participate	in	this	study	because	he/she	is	between	the	ages	of	7-15	
and	is	a	healthy	child	with	no	history	of	heart	problems.	This	study	is	looking	at	the	physical	and	
mental	health	of	children	with	congenital	heart	defects	compared	to	healthy	children.		
	
Your	child’s	participation	is	voluntary.	It	is	up	to	him/her	and	you	to	decide	whether	or	not	he/she	
wishes	to	take	part.	If	your	child	wishes	to	participate,	you	will	be	asked	to	sign	this	form.	If	he/she	
does	decide	to	take	part	in	this	study,	he/she	is	still	free	to	withdraw	at	any	time	and	without	giving	
any	reasons	for	the	decision.	
	
Please	take	time	to	read	the	following	information	carefully.	You	can	ask	the	researcher	to	explain	
any	words	or	information	that	you	do	not	clearly	understand.	You	may	ask	as	many	questions	as	you	
need.	Please	feel	free	to	discuss	this	with	your	family,	friends	or	family	physician	before	you	decide.	
	
WHO	IS	CONDUCTING	THE	STUDY?		
The	study	is	led	by	Dr.	Marta	Erlandson,	a	faculty	member	in	the	College	of	Kinesiology	at	the	
University	of	Saskatchewan.	This	research	is	funded	by	the	Children’s	Hospital	Foundation	of	
Saskatchewan.	Neither	the	University	nor	any	of	the	investigators	will	receive	any	direct	financial	
benefit	for	conducting	this	study.		
	
WHY	IS	THIS	STUDY	BEING	DONE?	
Congenital	heart	defects	are	the	world’s	leading	type	of	birth	defect.	Children	with	congenital	heart	
defects	have	higher	rates	of	physical	inactivity	and	obesity	compared	to	healthy	peers.	This	may	
mean	that	children	with	congenital	heart	defects	are	more	likely	to	have	chronic	conditions	such	as	
heart	disease	and	poor	bone	health	(osteoporosis)	later	in	life.	It	has	also	been	found	that	children	
with	congenital	heart	defects	have	high	levels	of	anxiety	around	physical	activity	participation.	While	
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we	know	that	children	with	congenital	heart	defects	have	higher	rates	of	obesity	little	is	known	
about	their	muscle,	bone	and	heart	health.	This	study	will	look	at	important	aspects	of	the	physical	
and	mental	health	of	children	with	congenital	heart	defects	compared	to	healthy	peers.			
	
WHO	CAN	PARTICIPATE	IN	THE	STUDY?		
Your	child	is	eligible	to	participate	in	this	study	if	he/she	is	aged	7-15	years	and	of	good	health.	Your	
child	is	not	eligible	if	he/she	has	any	type	of	heart	issues	or	other	health	condition	that	affects	
his/her	ability	to	perform	physical	activity.			
	
WHAT	DOES	THE	STUDY	INVOLVE?	
	
If	your	child	decides	to	participate	in	the	study	it	will	involve	a	single	visit	to	the	Physical	Activity	
Complex	(PAC)	at	the	University	of	Saskatchewan.	The	visit	will	take	approximately	four	hours.		Your	
child	will	be	requested	to	complete	a	form	with	his/her	personal	information	(such	as	name,	
telephone	number,	and	date	of	birth)	and	will	also	be	asked	to	complete,	with	your	assistance	if	
needed,	questionnaires	regarding	his/her	general	health	history,	physical	activity	and	psychological	
well-being	(health	related	anxiety	questionnaires).	We	will	measure	the	following:		
1. Your child’s height, sitting height, weight, waist circumference, and limb length.  
2. Your child’s body composition using DXA (dual energy x-ray absorptiometry). DXA is a 
scan that is done while your child lies on his/her back on what looks like a padded x-ray table. 
We will measure his/her total body, hip and spine. The scan assesses total body bone, muscle 
and fat tissues. The scans take approximately 10 minutes and will expose your child to a 
minimal amount of radiation (less than 5µSV). 
3. Your child’s bone shape and strength using a peripheral quantitative computed tomography 
(pQCT) scan of his/her non-dominant forearm and lower leg (each scan takes about 2 
minutes). For these scans your child will sit on a padded chair with his/her arm or leg resting 
on a support. All tests are painless and non-invasive. pQCT is a form of x-ray and therefore 
does emit  a small amount of radiation. The total radiation for all measurements (DXA and 
pQCT) is less than 4µSV this is comparable to the amount of background radiation a person 
receives in two days from naturally-occurring sources in Saskatchewan. For reference a cross-
country flight could expose a person to about 30µSV of radiation (http://www.hc-sc.gc.ca/hc-
ps/ed-ud/respond/nuclea/measurements-mesures-eng.php).  All scans will be administered by 
trained and certified personnel.     
4. Your child’s heart health using the seven following tests:  
A) Three small stickers will be attached to your child’s shoulders and stomach. The stickers 
are connected with a wire to our computer and will tell us about your child’s heartbeat. The 
stickers are gentle on the skin. They are the same stickers that the hospital uses when it 
measures heart activity. The stickers are thrown away after we are done the measure. With the 
stickers we will measure your child’s heart activity while he/she lies on his/her back for ten 
minutes. This test does not cause any discomfort and there are no health risks associated with 
this test.  
B) The second test will measure your child’s blood vessels. This will be done using a special 
machine at the same time as the first test. The machine uses a special pen that is placed on the 
skin to give a picture of your child’s blood pressure. The test will tell us about the health of 
the blood vessels and requires your child to lie still for about 5 minutes. This test does not 
cause any discomfort and there are no health risks associated with it.  
C) The third test will measure how your child’s nerves and blood vessels work. This will be 
done by having your child squeeze a hand gripper for two minutes. After this we will inflate a 
blood pressure cuff and will keep it inflated for two to three minutes. While the cuff is 
inflated we will monitor your child’s blood pressure. The handgrip test will be repeated 
without inflating a blood pressure cuff. During both handgrip tests we will measure blood 
pressure. This test can cause a slight tingling sensation in the arm from the blood pressure 
cuff. The sensation goes away when the cuff pressure is released.  
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D) Your child’s fitness will be tested with a low-intensity walk test. We want to know how 
far your child can walk in 6 minutes. Your child will walk at his/her own speed back and 
forth in a hallway for 6 minutes. We will measure your child’s heart rate and blood pressure 
before and after the walk test. The walk test is safe for most individuals because it is of low 
intensity and your child chooses how fast or slow he/she walks. We will closely monitor your 
child during the walk test and he/she will choose how fast or slow he/she walks. 
E)	Your	child’s	fitness	will	also	be	testing	using	a	stationary	exercise	bike	while	they	breathe	
through	a	special	mouthpiece	that	measures	how	much	oxygen	they	use	during	exercise.	
This	test	will	take	5	to	10	minutes.	We	will	measure	your	child’s	blood	pressure	and	monitor	
their	breathing	and	heart	activity.		This	test	is	also	safe	for	the	general	population.	This	test	
will	take	a	total	of	30	minutes.		
F)	Your	child’s	heart	structure	and	function	will	be	assessed	using	cardiac	ultrasound.	This	
assessment	will	entail	your	child	lying	restfully	on	their	side	for	30	minutes.	During	this	time,	
Dr.	Timothy	Bradley	(Pediatric	Cardiologist)	will	use	a	special	ultrasound	machine	to	take	
pictures	of	your	child’s	heart.	The	assessment	will	entail	performing	a	series	of	images	by	
placing	a	probe	in	different	positions	over	your	child’s	chest.	This	assessment	is	very	safe,	
low	risk,	is	entirely	non-invasive,	and	places	no	stress	on	your	child.	This	test	will	take	a	total	
of	30	minutes.	
G)	Your	child’s	blood	vessel	function	will	also	be	measured	using	vascular	ultrasound.	This	
assessment	will	be	performed	while	your	child	is	doing	the	handgrip	exercise	test	described	
in	#3	above.	The	assessment	will	entail	placing	a	probe	over	your	child’s	arm.	This	
assessment	is	very	safe,	low	risk,	is	entirely	non-invasive,	and	places	no	stress	on	your	child.	
This	test	will	not	add	any	time	to	your	child’s	session.	
	
 
	
After	the	visit	to	the	University,	your	child	will	also	be	asked	to	wear	an	accelerometer	for	7	
consecutive	days.	An	accelerometer	is	a	type	of	motion	sensor	that	measures	your	child’s	physical	
activity.		It	is	a	small	device	that	will	be	worn	around	your	child’s	waist	on	an	elastic	belt.	He/she	will	
be	asked	to	put	it	on	first	thing	in	the	morning	and	wear	it	all	day	except	when	bathing,	swimming	or	
playing	contact	sports.		During	your	visit	at	the	University	you	will	be	provided	with	an	addressed	
and	stamped	envelope	to	return	the	accelerometer	after	the	seven	days	of	wear.		
				
WHAT ARE THE BENEFITS OF PARTICIPATING IN THIS STUDY?  
There	may	be	no	direct	benefit	to	your	child	from	participating	in	this	study.	It	is	hoped	that	the	
information	gained	from	this	study	will	positively	affect	the	health	of	children	with	congenital	heart	
defects	and	contribute	to	the	development	of	a	program	to	promote	physical	activity	and	healthy	
lifestyle	counseling	for	this	population.		
	
ARE	THERE	POSSIBLE	RISKS	AND	DISCOMFORTS?	
The	risks	of	participating	are	the	minimal.	The	fitness	test	on	a	stationary	bike	will	assess	your	child’s	
exercise	capacity.	During	this	test,	your	child	may	feel	a	few	minutes	of	physical	fatigue	that	comes	
with	exercise.	They	also	may	experience	some	leg	soreness	as	a	consequence	of	this	test,	but	this	
should	disappear	within	2	days.	This	stationary	bike	test	is	safe	and	the	intensity	of	how	hard	your	
child	exercises	is	determined	by	your	child.	As	stated	above	the	bone	measures	(DXA	and	pQCT)	will	
expose	your	child	to	a	minimal	amount	of	radiation.	The	tests	are	very	low	risk;	the	total	radiation	
dose	for	the	study	is	less	than	half	of	that	of	a	standard	chest	x-ray.	As	with	any	physical	activity	
there	is	a	slight	risk	that	your	child	may	experience	sore	muscles	after	the	six	minute	walk	test.	If	
your	child	experiences	soreness	it	will	not	last	very	long.		
				
WHAT HAPPENS IF I DECIDE TO WITHDRAW? 
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Your	child’s	participation	in	this	research	is	voluntary.	He/she	may	withdraw	from	this	study	at	any	
time.	You	do	not	have	to	provide	a	reason.		
	
If	your	child	chooses	to	enter	the	study	and	then	decides	to	withdraw	later,	all	data	collected	about	
him/her	during	his/her	enrolment	will	be	retained	for	analysis.		
	
WHAT WILL THE STUDY COST ME? 
You will not be charged for any research-related procedures and your child will not be paid for 
participating in this study. Your parking costs at the University will be covered.  
	
WHAT HAPPENS IF SOMETHING GOES WRONG?  
In the unlikely event that your child is injured while participating in this research, appropriate medical 
care will be provided at no cost to you. By signing this document, you and your child do not waive 
any of your legal rights.   
	
WILL	MY	TAKING	PART	IN	THIS	STUDY	BE	KEPT	CONFIDENTIAL?	
Your	child’s	confidentiality	will	be	respected.		No	information	that	discloses	your	child’s	identity	will	
be	released	or	published	without	your	specific	consent	to	the	disclosure.		The	results	of	this	study	
may	be	presented	in	a	scientific	meeting	or	published,	but	your	child’s	identity	will	not	be	disclosed.		
	
WHO	DO	I	CONTACT	IF	I	HAVE	QUESTIONS	ABOUT	THE	STUDY?	
If	 you	 have	 any	 questions	 or	 desire	 further	 information	 about	 this	 study	 before	 or	 during	
participation,	 you	 can	 contact	 Marta	 Erlandson	 by	 phone	 at	 306-966-1071	 or	 by	 email	 at	
marta.erlandson@usask.ca.	
	
If	you	have	any	concerns	about	your	child’s	rights	as	a	research	participant	and/or	your	experiences	
while	participating	in	this	study,	contact	the	Chair	of	the	University	of	Saskatchewan	Research	Ethics	
Board,	at	306-966-2975(out	of	town	calls	1-888-966-2975).	The	Research	Ethics	Board	is	a	group	of	
individuals	(scientists,	physicians,	ethicists,	lawyers	and	members	of	the	community)	that	provide	an	
independent	review	of	human	research	studies.	This	study	has	been	reviewed	and	approved	on	
ethical	grounds	by	the	University	of	Saskatchewan	Research	Ethics	Board.		
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A	Pilot	Health	Intervention	Study	of	Children	with	Congenital	Heart	Defects:	CHAMPS	–	Children’s	
Healthy	Heart	Camp	in	Saskatchewan	
 
 
o I have read (or someone has read to me) the information in this consent form. 
o I understand the purpose and procedures and the possible risks and benefits of the study.  
o I was given sufficient time to think about it. 
o I had the opportunity to ask questions and have received satisfactory answers. 
o I	understand	that	my	child	is	free	to	withdraw	from	this	study	at	any	time	for	any	reason.		
o I	have	been	informed	that	there	is	no	guarantee	that	this	study	will	provide	any	benefits	to	
my	child.		
o I give permission to the use and disclosure of my child’s de-identified information collected 
for the research purposes described in this form. 
o I understand that by signing this document I do not waive any of my or my child’s legal 
rights. 
o I understand I will be given a signed copy of this consent form. 
	
	
I	agree	to	allow	my	child	to	participate	in	this	study:	
	
	
Printed	name	of	person	providing	consent:	______________________________	
Signature	of	Consenting	Parent:		 	Date	____________	
	
	
Printed	name	of	person	obtaining	consent:			_________________________________	
Signature			 	Date	___________	
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PARTICIPANT INFORMATION AND ASSENT FORM 
	
A	Pilot	Health	Intervention	Study	of	Children	with	Congenital	Heart	Defects:	CHAMPS	–	Children’s	
Healthy	Heart	Camp	in	Saskatchewan	
	
Researchers:		 	 	 	
Dr.	Marta	Erlandson,	College	of	Kinesiology	 			 Dr.	Kristi	Wright,	University	of	Regina	 		
Email:	marta.erlandson@usask.ca	 	 	 Email:	Kristi.wright@uregina.ca	
Phone:	306-966-1071	 	 	 	 	 Phone:	306-585-4772	
	
Dr.	Corey	Tomczak,	College	of	Kinesiology	 	 Dr.	Ashok	Kakadekar,	Pediatric	Cardiology		
Email:	corey.tomczak@usask.ca		 	 	 Email:	a.kakadekar@usask.ca			
Phone:	306-966-1066	 	 	 	 	 	
	
 
Introduction 
This form may use words you do not understand. Please ask the person explaining the study 
to explain any words or information that you do not clearly understand. 
You are being asked to take part in a research study because when you were born your 
heart didn’t work exactly as it was supposed to. The study will help us find out more about 
your muscle, bone and heart health. It will also help us learn how you feel about participating 
in physical activity.  
 
A research study is something like a science project in school. The people who are doing 
this study want to learn something new about children who are born with heart problems like 
the one you have and how you feel about physical activity and exercise. When the study is 
over, they will see what kinds of activities are the best for you to participate in. At the end of 
the study the researchers want you to feel more comfortable and confident in participating in 
different physical activities at school and with your friends.  
 
What happens in this Study?  
The study will be done at the College of Kinesiology on the University Campus. You will 
come to the university two times. The first time you come the researchers will ask you to fill 
in some questionnaires which your parents can help you with if you would like. The 
researchers will then measure how tall you are, how much you weigh and how long your 
lower arm and leg are. The researchers will measure your bones using two special imaging 
machines. One of the machines will take a picture of your whole body while you lay on a bed 
and the other one will take a picture of your arm and leg bones. The researchers will also 
measure your heart and the veins and arteries that carry your blood around your body and to 
your heart using four different tests. For the first test they will put stickers on your shoulders 
and stomach while you lay on a bed. The stickers will read what your heart is doing, you will 
not feel anything. For the second test you will have to lie still while the researcher measures 
your blood vessels with a special pen. Again you will not feel anything while they take this 
measurement. For the third test, you will squeeze your hand on a special machine for two 
minutes while the researcher measures your blood pressure. The researcher will also take a 
picture of your blood vessels. For the forth test you will be asked to walk at whatever speed 
you would like for 6 minutes. For the fifth test you will be asked to pedal on a bike your 
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breathing is measured. For the last test you will be asked to lie still while a researcher takes 
pictures of your heart. After finishing these activities the researchers will give you a small 
device (motion sensor) that you will wear on your hip for seven days. 
 
For the second part of the study you will come back to the College of Kinesiology for a week 
in August. This part of the study will be similar to summer camp. Each day you will 
participate in different physical activities like swimming and playing in the gym. You will also 
learn skills to help you feel more comfortable about participating in physical activity as well 
as healthy eating and heart health.   
 
You will be asked to wear the small motion sensor on your hip for seven days again after the 
camp has finished.  
 
If you agree the researchers may also take pictures of you while are you participating in the 
study. The pictures would be used only for research or teaching presentations and your face 
would be blacked out so no one would be able to recognize you.  
 
You do not have to agree to be in this study.  
 
Withdrawal from Study 
You do not have to be in this study and you can stop being in this study at any time.  If you 
say yes now, but change your mind later, you can say no and that will be okay. If you decide 
not to participate, no one will be upset or disappointed.  
ASSENT 
I have read this paper or have had it read to me.  I understand what I have to do in this 
study and I agree to take part in it.   
 
 
______________________________________________ 
Child’s Name (Print) 
 
 
______________________________________________  _______________ 
Child’s Signature     Date 
 
 
       It is okay for the researchers to take my picture   
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Check which applies (to be completed by person administering assent): 
 The subject is capable of reading and understanding the assent form and has signed 
above as documentation of assent to take part in this study. 
 
 The subject is not capable of reading the assent form, however, the information was 
explained verbally to the subject who has verbally given assent to take part in this 
study. 
 
 
________________________________________________ 
Name of Person Administering Assent (Print) 
 
________________________________________________          __________________ 
Signature of Person Administering Assent                                    Date 
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PARTICIPANT INFORMATION AND ASSENT FORM 
	
A	Pilot	Health	Intervention	Study	of	Children	with	Congenital	Heart	Defects:	CHAMPS	–	Children’s	
Healthy	Heart	Camp	in	Saskatchewan	
	
Researchers:		 	 	 	
Dr.	Marta	Erlandson,	College	of	Kinesiology	 			 Dr.	Kristi	Wright,	University	of	Regina	 		
Email:	marta.erlandson@usask.ca	 	 	 Email:	Kristi.wright@uregina.ca	
Phone:	306-966-1071	 	 	 	 	 Phone:	306-585-4772	
	
Dr.	Corey	Tomczak,	College	of	Kinesiology	 	 Dr.	Ashok	Kakadekar,	Pediatric	Cardiology		
Email:	corey.tomczak@usask.ca		 	 	 Email:	a.kakadekar@usask.ca		
Phone:	306-966-1066	 	 	 	 	 	
	
	
 
Introduction 
This form may use words you do not understand. Please ask the person explaining the study 
to explain any words or information that you do not clearly understand. 
You are being asked to take part in a research study because you are a healthy person. The 
study will help us find out more about your muscle, bone and heart health.  
 
A research study is something like a science project in school. The people who are doing 
this study want to learn something new about children who are born with heart problems. 
When the study is over, they will see how muscle, bone and heart health is different in 
children with heart problems compared to healthy children.  
 
What happens in this Study?  
The study will be done at the College of Kinesiology on the University Campus. When you 
come in the researchers will ask you to fill in some questionnaires which your parents can 
help you with if you would like. The researchers will then measure how tall you are, how 
much you weigh and how long your lower arm and leg are. The researchers will measure 
your bones using two special imaging machines. One of the machines will take a picture of 
your whole body while you lay on a bed and the other one will take a picture of your arm and 
leg bones. The researchers will also measure your heart and the veins and arteries that 
carry your blood around your body and to your heart using four different tests. For the first 
test they will put stickers on your shoulders and stomach while you lay on a bed. The 
stickers will read what your heart is doing, you will not feel anything. For the second test you 
will have to lie still while the researcher measures your blood vessels with a special pen. 
Again you will not feel anything while they take the measurement. For the third test, you will 
squeeze your hand on a special machine for two minutes while the researchers measure 
your blood pressure. The researcher will also take pictures of your blood vessels. For the 
forth test you will be asked to walk at whatever speed you would like for 6 minutes. For the 
fifth test you will be asked to pedal on a bike your breathing is measured. For the last test 
you will be asked to lie still while a researcher takes pictures of your heart. After finishing 
these activities the researchers will give you a small device (motion sensor) that you will 
wear on your hip for seven days. 
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You do not have to agree to be in this study.  
 
 
 
Withdrawal from Study 
You do not have to be in this study and you can stop being in this study at any time.  If you 
say yes now, but change your mind later, you can say no and that will be okay. If you decide 
not to participate, no one will be upset or disappointed.  
 
ASSENT 
I have read this paper or have had it read to me.  I understand what I have to do in this 
study and I agree to take part in it.   
 
 
______________________________________________ 
Child’s Name (Print) 
 
 
____________________________________________       _______________________ 
Child’s Signature     Date 
 
 
 
 
Check which applies (to be completed by person administering assent): 
 The subject is capable of reading and understanding the assent form and has signed 
above as documentation of assent to take part in this study. 
 
 The subject is not capable of reading the assent form, however, the information was 
explained verbally to the subject who has verbally given assent to take part in this 
study. 
 
 
________________________________________________ 
Name of Person Administering Assent (Print) 
 
 
________________________________________________ ____________________ 
Signature of Person Administering Assent                                     Date 
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MAP:  
2×3 Repeated Measures ANOVA. Greenhouse-Geisser correction used for condition because 
assumption of sphericity was violated. 
 Group: F (1,8) = 17.339, P = 0.003 
 Condition: FGG (1.136, 9.092) = 22.900, P = 0.001 
 Interaction: F (2,16) = 9.146, P = 0.002 
HR:  
2×3 Repeated Measures ANOVA. 
 Group: F (1,8) = 4.002, P < 0.001 
Condition: F (2, 16) = 63.611, P = 0.015 
 Interaction: F (2,16) = 12.204, P = 0.001 
FBF:  
2×3 Repeated Measures ANOVA. Greenhouse-Geisser correction used for condition and 
interaction because assumption of sphericity was violated. 
 Group: F (1,7) = 0.146, P = 0.473 
 Condition: FGG (1.141, 7.985) = 5.232, P = 0.048 
Interaction: FGG (1.141, 7.985) = 2.146, P = 0.182 
SVR:  
2×3 Repeated Measures ANOVA. 
 Group: F (1,7) = 0.146, P = 0.714 
 Condition: F (2,14) = 3.687, P = 0.052 
Interaction: F (2,14) = 7.968, P = 0.005 
VE:  
2×3 Repeated Measures ANOVA. Mann-Whitney U Rank Sum Test used for handgrip and  
PECO because assumption of homogeneity of variance was violated. 
 Group: F (1,8) = 4.002, P = 0.08 
 Condition: F (2,16) = 5.461, P = 0.016 
Interaction: F (2,16) = 4.507, P = 0.028 
Handgrip: U = 18, P = 0.047 
PECO: U = 29, P = 0.310 
TV:  
2×3 Repeated Measures ANOVA. Greenhouse-Geisser correction used for condition and 
interaction because assumption of sphericity was violated. Mann-Whitney U Rank Sum Test 
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used for handgrip and PECO because assumption of homogeneity of variance was violated. 
 Group: F (1,8) = 16.629, P = 0.004 
 Condition: FGG (1.253, 10.025) = 4.154, P = 0.062 
Interaction: FGG (1.166, 9.331) = 5.098, P = 0.045 
Handgrip: U = 15, P = 0.024 
PECO: U = 33, P = 0.508 
f:  
2×3 Repeated Measures ANOVA. 
 Group: F (1,8) = 0.382, P = 0.554 
 Condition: F (2,16) = 2.136, P = 0.151 
Interaction: F (2,16) = 0.119, P = 0.888 
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HLHS-FC  CTL 
Participant  MVC (N)  Participant  MVC (N) 
1  117  10  355 
2  102  11  141 
3  236  12  161 
4  99  13  234 
5  77  14  345 
6  279  15  125 
7  64  16  262 
8  229  17  263 
9  103  18  451 
Mean   145*  Mean  260 
SD  80  SD  109  
 
*P = 0.022 by unpaired t-test. 
 
